2011 Research Report

understanding life IMPROVING HEALTH University Health Network (UHN) consists of the Toronto General Hospital (TGH), Toronto Western Hospital (TWH) and Princess Margaret Hospital (PMH). The scope of research and complexity of cases at UHN have made it a national and international source for discovery, education and patient care. It has the largest hospital-based research program in Canada, with major research in transplantation, cardiology, neurosciences, oncology, surgical ‹‘˜ƒ–‹‘ǡ‹ˆ‡ –‹‘—•†‹•‡ƒ•‡•ƒ†‰‡‘‹ ‡†‹ ‹‡Ǥ ‹•ƒ”‡•‡ƒ” ŠŠ‘•’‹–ƒŽƒƥŽ‹ƒ–‡† with the University of Toronto (UT). TABLE OF CONTENTS

Welcome Message 3

The Research Hospital of the Future 4

Toronto Rehab Joins UHN 6

Pioneering Stem Cell Research 8

TGRI Welcomes Acclaimed New Director 10

Year in Review 12

Honour Roll 18

Funding 21 UHN’s Supporting Foundations

Research 24 Mechanisms of Disease Experimental Therapeutics Medical Technology Informatics Health Services Research

Institutes 37 Ontario Cancer Institute (OCI) Toronto General Research Institute (TGRI) Toronto Western Research Institute (TWRI)

Financial Information 45

UHN Research Committees 46

External Sponsors 48 Senior Scientists 146 Scientists 42 ƥŽ‹ƒ–‡ ‹‡–‹•–• 76 Assistant Scientists 4 CSRC/CRU Members 271 Total Researchers 539

Fellows 452 Graduate Students 400 Total Trainees 852

‡ Š‹ ƒŽƒ†—’’‘”––ƒơ 1,410 Research Space 745,000 sq ft Publications 1,915 UHN RESEARCH: A SNAPSHOT A UHN RESEARCH: Total Funding $253,245,000

Philip Branton, PhD (Chair) Gilman Cheney Professor, Departments of Biochemistry and Oncology, McGill University Victor Dzau, MD Šƒ ‡ŽŽ‘”ˆ‘” ‡ƒŽ–Šơƒ‹”•ǡ ƒ‡•Ǥ—‡”‘ˆ‡••‘” of Medicine and Director of Molecular and Genomic Vascular Biology, Duke University; President and CEO, Duke University Health System John Parrish, MD Š‹‡ˆš‡ —–‹˜‡ƥ ‡”ƒ†‘Ǧ ‘—†‡”ǡ‡–‡”ˆ‘” Integration of Medicine & Innovative Technology Ralph Steinman, MD† Senior Physician and Henry G. Kunkel Professor, Laboratory of Cellular Physiology and Immunology, Director of the Christopher H. Browne Center for Immunology and Immune Diseases, The Rockefeller University Hans Wigzell, MD, PhD Professor Emeritus of Immunology, Department of Microbiology, Tumor and Cell Biology, Karolinska Institute INTERNATIONAL RESEARCH ADVISORY BOARD ADVISORY RESEARCH INTERNATIONAL

University Health Network Research Report 2011Ǥ—„Ž‹•Š‡†„›–Š‡ƥ ‡‘ˆ–Š‡‹ ‡”‡•‹†‡–ǡ‡•‡ƒ” Šǡ Ǥ ”ƒ’Š‹ †‡•‹‰ǡ™”‹–‹‰ƒ†’”‘†— –‹‘„› UHN Research Communications. Data provided by UHN Research Support Services. Respective data types are accurate as of December 31, 2010 (publication ‘—–›‡ƒ”Ǧ‡†Ȍǡƒ” Š͙͛ǡ͚͙͙͘ȋƤ• ƒŽ›‡ƒ”Ǧ‡†Ȍ‘” —‡͛͘ǡ͚͙͙͘ȋƒ ƒ†‡‹ ›‡ƒ”Ǧ‡†ȌǤŠ‘–‘‰”ƒ’Š• ‘—”–‡•›‘ˆ‡Œƒ‹ƒ—–•ǡ—ƒ‡™ǡ„”‘•‹‘ ‹ƒ‰‹„ƒǡƒ”• ƒ‰„‡”‰ǡƒƒ†ƒ‡™•™‹”‡ƒ†˜ƒ”‹‘—••‘—” ‡•‹ Ž—†‹‰ ‘Š‘’‡”ȋ Š‘–‘‰”ƒ’Š‹ •ȌǤ‘‡Ƥ‰—”‡•ƒ›„‡”‘—†‡†ƒ†Ȁ‘”ƒ› include data not represented in Institute data. Publications jointly authored by investigators at multiple UHN Institutes are counted only once in the UHN ‡•‡ƒ” Š–‘–ƒŽǤ‡•‡ƒ Š‡”•™Š‘Šƒ˜‡‘”‡–Šƒ‘‡ƒƥŽ‹ƒ–‹‘™‹–Š‹ƒ •–‹–—–‡ǡ‘”„‡–™‡‡ •–‹–—–‡•ǡƒ”‡‘Ž›‹ Ž—†‡†‘ ‡‹–Š‡–‘–ƒŽ ‘—–Ǥ‘–ƒŽ funding includes external and core funding. †Dr. Steinman passed away September 30, 2011. 2 Welcome Message

†‡”•–ƒ†‹‰Ž‹ˆ‡ ƒ‡ƒ†‹ơ‡”‡––Š‹‰•–‘†‹ơ‡”‡– Upeople. At UHN, we seek to improve health by understanding life at several levels.

Our quest begins with looking into the life of a cell. Heart cells, blood cells, lung cells, brain cells—all are highly specialized units with unique abilities. The life of a cell involves a myriad of molecular and biochemical interactions, genes switched ‘ơƒ†‘ǡ’”‘–‡‹•–Šƒ–ƒ ——Žƒ–‡ƒ†–Š‡†‹••‘Ž˜‡ and, in many cases, a planned and programmed death. Our understanding of the normal life of a cell is the basis for detecting and assessing deviations from the norm which can have catastrophic consequences including the malignant

transformation of tumours and the failure of pancreatic UHN PRESIDENT AND CEO, islet cells to produce insulin. To improve health, we need to understand the life of a cell. Robert S. Bell, MDCM, MSc, FACS, FRCSC Cells do not act in isolation so we also have to understand the With rare exceptions, the human body needs all of its organs life of networks of cells. These networks can result in compact, and cellular networks to function properly and work together as an interconnected system. The components of the system ‡š‡”– ”‹–‹ ƒŽ‹ƪ—‡ ‡‘‡ƒ Š‘–Š‡”ǡ™Š‹ Š‹•™Š›‹–‹•–Š‡”—Ž‡ rather than the exception that co-morbidities are common. To improve health, we also need to understand how systems are related and regulated.

Just as cells interact to form networks to achieve critical functions – so too do people. Understanding the life of an organization like a research hospital is one of our most important tasks. How can specialists be brought together to develop and deliver multidisciplinary care to complex cases? How can we enhance the patient experience both in terms of outcomes and satisfaction? How can we improve the delivery of health care to ensure sustainability while maintaining quality? To improve health, we absolutely need to understand VICE PRESIDENT, RESEARCH, UHN RESEARCH, VICE PRESIDENT, ourselves, and to use UHN as a living laboratory where we can Christopher J. Paige, PhD, FCAHS study and optimize how we deliver care to improve health. highly structured organs like a heart where cell connectivity At UHN, our goal is to understand ‘life’ at all of these levels and results in regular rhythmic contraction, or skin where ‹–‡” ‘‡ –‡†Žƒ›‡”•‘ˆ ‡ŽŽ•ˆ‘”–Š‡Ƥ”•–Ž‹‡‘ˆ†‡ˆ‡•‡‹ to use that understanding to improve health. We accomplish a hostile world of infection. Other networks are composed this by attracting and retaining some of the world’s best of widespread, highly mobile units like the immune system medical researchers and practitioners and partnering with the which permeates throughout the body. In all cases, cells University of Toronto and our hospital neighbours to use this communicate with each other through electrical, chemical or knowledge to improve health. We invite you to read through physical signals and a breakdown in this communication can this report for a glimpse of how we’ve pursued this quest to lead to movement disorders, heart failure or autoimmune understand life and impact patient care by improving health in disease, among others. To improve health, we need to 2011. understand cellular networks. 3 The Research Hospital of the Future

4 UHN Strategic Planning

n early 2011, UHN’s Board of Trustees approved UHN Research, led by Vice President, Research Dr. Ithe hospital’s new strategic plan entitled University Š”‹•–‘’Š‡”ƒ‹‰‡ǡŠƒ•‡•–ƒ„Ž‹•Š‡†Ƥ˜‡’”‹‘”‹–›–Š‡‡• Health Network Strategic Directions 2016 – Global that will act as our guiding principles in realizing these Impact, Local Accountability. This new corporate goals: plan—a culmination of an institution-wide planning initiative led by President and CEO Dr. Robert Bell— Mechanisms of Disease is informed by the strategic directions of UHN’s Experimental Therapeutics programs and will enable the innovative ambitions of Medical Technology –Š‡•‡’”‘‰”ƒ•‘˜‡”–Š‡‡š–Ƥ˜‡›‡ƒ”•Ǥ –‹•‘”‰ƒ‹œ‡† „›–Š‡Ƥ˜‡’”‹‘”‹–›†‘ƒ‹•‹†‡–‹Ƥ‡†‹ ǯ• Informatics purpose statement, “We are a caring, creative, and Health Services Research accountable academic hospital transforming health care for our patients, community, and the world.” In the long-term, the goals of the research priority themes and the input from the UHN community will In this document, the creative domain, UHN’s research culminate in a roadmap by April 2012. ƒ†‹‘˜ƒ–‹‘ ‘”‡ǡŠƒ•‹†‡–‹Ƥ‡†‹–••–”ƒ–‡‰‹ –Š‡‡ as “Become the Research Hospital of the Future”—this Health Services Research: A New Priority is the hospital that we envision UHN becoming in the next 15-20 years. To do this, it will pursue three goals: UHN’s expansive environment provides a unique venue to study and improve the delivery of health care Further our understanding of the basis of through the conduct of health services research (HSR). health and disease through biology and HSR has a presence at UHN in the context of academic technology platforms research and quality improvement, assurance and organizational development, but has not previously Leverage experimental therapeutics and been formally acknowledged. As the result of ongoing health services to impact the lives of strategic planning, HSR is now recognized by UHN patients as a platform, joining other systematically organized areas of research. This will strengthen the vital role Enable the collection, analysis and HSR plays in ensuring that health care remains at the application of health information forefront of innovation and continually improves, along with the health and well-being of patients.

“The roadmap will be a ‘living’ document that will strategically evolve with trends in innovation and health care. It will guide UHN’s path to becoming the Research Hospital of the Future.” - Dr. Christopher Paige

5 Toronto Rehab Joins UHN

uly 1, 2011 marked the integration of UHN with the Toronto JRehabilitation Institute (Toronto Rehab). This merger, which brings –‘‰‡–Š‡”ˆ‘—”Š‘•’‹–ƒŽ•ƒƥŽ‹ƒ–‡†™‹–Š–Š‡‹˜‡”•‹–›‘ˆ‘”‘–‘ǡ™‹ŽŽ facilitate the process of health care, and all aspects of care—from diagnosis and treatment through to rehabilitation and recovery. Toronto Rehab President and CEO Mark Rochon explains, “Bringing these two organizations together will enable clinicians to initiate rehabilitation much sooner in the acute care phase of treatment which will enhance the quality and continuity of care as well as outcomes for patients.” The ‹–‡‰”ƒ–‹‘‘ˆ–Š‡•‡™‘”Ž†Ǧ Žƒ••Š‘•’‹–ƒŽ•™‹ŽŽ’”‘˜‹†‡Ž‘‰Ǧ–‡”„‡‡Ƥ–• for the health care system as a whole.

Research at UHN has also expanded to include Toronto Rehab’s research program, which was created in 2001 with a grant from the Ontario Ministry of Health and Long-Term Care. The goal of this program is –‘†‡˜‡Ž‘’‡™ƒ†‘”‡‡ơ‡ –‹˜‡–”‡ƒ–‡–•ǡƒ••‹•–‹˜‡†‡˜‹ ‡•ƒ† technologies to help people live as fully and independently as possible. Research at Toronto Rehab focuses on three priority areas: preventing accidents and injuries; providing post-acute care to help people return to as full participation in society as possible after their treatment; and helping older people and people with disabilities and their family caregivers continue to live in their own homes as they age. Toronto Rehab Šƒ•‹‡–‡ƒ•–Šƒ–™‘”‘–Š‡•‡’”‹‘”‹–›ƒ”‡ƒ•ǣƒ”–‹Ƥ ‹ƒŽ‹–‡ŽŽ‹‰‡ ‡ ƒ†”‘„‘–‹ •ǡ ƒ”†‹‘’—Ž‘ƒ”›Ƥ–‡••ǡ ‘‰‹–‹‘ǡ ‘—‹ ƒ–‹‘ǡ mobility, neural engineering and therapy, optimization of the rehabilitation system, sleep and the upper airway and technology.

Toronto Rehab is home to the most advanced rehabilitation research facilities in the world. These facilities include seven simulated environments for developing and testing systems that range from

is a fabulous opportunity to address problems that e experience before and after being acute care –•ǤŠ‡‹–‡‰”ƒ–‹‘‘ˆ‘—”‡ơ‘”–•™‹ŽŽ•–”‡‰–Š‡ prevention and reintegration into society,”” Ȃ”Ǥ ‡‘ơ , Institute Director of Toronto Rehab

8 ”Ǥ ‡‘ơ ‡”‹‡ȋ ‡–”‡Ȍƒ†•‘‡‘ˆ‘”‘–‘‡Šƒ„•–ƒơ technologies in the home to help people maintain their ƒ”‡ Ž‡ƒ”Ž›ƒ›’”‘‰”ƒ•ƒ– ™Š‹ Š•–ƒ†–‘„‡‡Ƥ– independence, through technologies in health care greatly from enhanced collaboration.” institutions to reduce stress on caregivers and support better hand hygiene, to better boots and shoes that “Everyone who has been part of this process has seen the reduce falls on ice and snow. enormous opportunity for patients, research and health care professionals in this new organization,” adds Dr. UHN Vice President, Research, Dr. Christopher Paige Robert Bell, President and CEO of UHN. “I am committed expresses his excitement over the joining of the Toronto to the vision for the new UHN which now combines Rehab research program, “Toronto Rehab has built an outstanding acute services with excellent post-acute care excellent program in rehabilitation research over the last in an environment that supports inter-professional care, †‡ ƒ†‡™‹–Šƒ—„‡”‘ˆ™‘”Ž†ǦƤ”•–‹‘˜ƒ–‹‘•ƒ†–Š‡”‡ education and research.”

(L-R) David Bragg (Chair, Toronto Rehab Board of Trustees), Mark Rochon, Dr. Robert Bell and John Mulvihill (Chair, UHN Board of Trustees) signing the Integration Agreement

7 Pioneering Stem Cell Research

Drs. James Till and Ernest McCulloch

he discovery of blood-forming stem cells by Drs. awards, including the coveted Gairdner Foundation TJames Till and Ernest McCulloch “...revolutionized International Award (1969) and the Albert Lasker our concepts of blood cell development and Award for Basic Medical Research (2005)—two of the ƒŽ–‡”‡†–Š‡ ‘—”•‡‘ˆ ƒ ‡””‡•‡ƒ” Š„›‘ơ‡”‹‰ƒ most prestigious medical science awards. rationale for bone marrow transplantation,” says Dr. Christopher Paige, Vice President, Research. On February 1, 2011—the 50th anniversary of the publication of their discovery—UHN held a tribute Š‹•†‹• ‘˜‡”›‘˜‡”–—”‡† ‘˜‡–‹‘„›†‡Ƥ‹‰ to acknowledge their accomplishments. Their work cells based on function rather than morphology. They has not only established Toronto as the birthplace created an assay to measure two trademarks of stem of the stem cell, but also as a centre for stem cell ‡ŽŽ•ǣ•‡ŽˆǦ”‡‡™ƒŽƒ†–Š‡ƒ„‹Ž‹–›–‘†‹ơ‡”‡–‹ƒ–‡‹–‘ innovation by inspiring the next generation of stem other cell types. Through further experiments, they cell researchers. ‡•–ƒ„Ž‹•Š‡†–Š‡Ƥ”•–’”ƒ –‹ ƒŽ†‡Ƥ‹–‹‘‘ˆƒ•–‡ ‡ŽŽǡ ’”‘˜‹†‹‰–Š‡•’ƒ”–Šƒ–‹‰‹–‡†–Š‡‡–‹”‡Ƥ‡Ž†‘ˆ stem cell research. Watch UHN and University of Toronto researchers describe the impact Drs. In recognition of their achievements, Drs. Till Till and McCulloch have had on their careers. and McCulloch were presented with numerous

8 Remembering Ernest McCulloch

r. McCulloch was born in 1926 in Toronto. DHe completed his medical degree at the ‹˜‡”•‹–›‘ˆ‘”‘–‘ƒ†–”ƒ‹‡†„”‹‡ƪ›ƒ– the Lister Institute in London, England, before returning to Toronto to begin his research career at the newly formed OCI in 1957. In addition to being an inspirational researcher and leader at OCI and the University of Toronto’s Institute of Medical Science, he was ƒŽ‘˜‹‰ƒ††‡˜‘–‡†ˆƒ–Š‡”–‘Š‹•Ƥ˜‡ Š‹Ž†”‡Ǥ Dr. McCulloch passed away on January 20, 2011.

Dr. McCulloch will be greatly missed at UHN. He will be remembered as a major advocate of collaboration: trained as a hematologist, he worked closely with Dr. Till, a biophysicist, in stem cell research, while the two maintained a lifelong friendship. He was known as a ‘big picture’ thinker, keeping his eye on the greater goal of therapeutic outcomes for cancer patients. He was also a mentor for young stem cell scientists. “Dr. McCulloch was truly an inspiration to decades of scientists,” says Dr. Mark Minden, OCI Senior Scientist and former trainee of Dr. McCulloch. His lifework will continue to have an impact internationally and at UHN, where his spirit of collaboration, ‘–‹˜ƒ–‹‘ƒ†• ‹‡–‹Ƥ ”‹‰‘”Ž‹˜‡•‘Ǥ

“The University of Toronto and UHN have a great champion.” – Dr. Christopher Paige

Learn more about the life of Dr. Ernest McCulloch.

Dr. Ernest McCulloch (1926-2011) TGRI Welcomes Acclaimed New Director

his past May, TGRI welcomed its new Director, Dr. Mansoor THusain. As a specialist in cardiovascular disease and nuclear cardiology, Dr. Husain brings outstanding clinical and research credentials to the role. He is currently a Senior Scientist at TGRI, Director of Research at UHN’s Peter Munk Cardiac Centre and Director of the Heart & Stroke/Richard Lewar Centre of š ‡ŽŽ‡ ‡ƒ––Š‡‹˜‡”•‹–›‘ˆ‘”‘–‘Ǥ ƒ††‹–‹‘ǡŠ‡‹•ƒƥŽ‹ƒ–‡† with the McEwen Centre for Regenerative Medicine and recently served as the President of the Canadian Hypertension Society.

As TGRI Director, Dr. Husain intends to improve the focus of the Institute and engage trainees in the research process. “I hope to better integrate the amazing human resources and infrastructure we have at TGRI into disease-focused research teams that interact in meaningful ways with hospital-based medical programs. I believe that this will be critical to increasing our capacity for patient-focused research and thus more rapidly enable innovations in patient care,” says Dr. Husain. “I also hope to re-launch resources for our investigators, including a TGRI Equipment Fund and a TGRI Trainee Awards Program. To build •‘‡‡–Š—•‹ƒ•ˆ‘”–Š‡•‡‹‹–ƒ‹–‹˜‡•ǡ›Ƥ”•–‰‘ƒŽ‹•–‘”‡ƒ Š out and engage our researchers and hospital leaders—I hope our •–ƒơ™‹ŽŽ•Šƒ”‡–Š‡‹”‹†‡ƒ•™‹–Š‡Ǥ ƒŠ‡”‡–‘Š‡Ž’–Š‡‘˜‡ forward.”

Dr. Husain’s own research program focuses on the molecular “We have a truly unique events controlling the growth and development of vascular combination of world smooth muscle cells and the creation of genetic and experimental class facilities, innovative models of cardiovascular disease. He received his MD degree researchers and dedicated from the University of Alberta in 1986. His subsequent clinical and research training was completed at St. Michael’s Hospital, health care professionals all UHN, the Massachusetts Institute of Technology and Harvard striving to answer questions Medical School. He has more than 60 publications and is the and provide solutions for recipient of a number of awards for his clinical and research work, including the Moshier Memorial Gold Medal from the University our patients.” of Alberta, the Allan Bruce Robertson Young Investigator Award from the Clinical Research Society of Toronto and the William Goldie Prize from the Department of Medicine at the University of Toronto. Dr. Husain replaced Dr. Richard Weisel, who served as Director from 2005 to 2011. 12 11 Year in Review Selected research events from 2011

UHN and UT Create New Institute HN, in collaboration with the University of Toronto U(UT), celebrated the launch of the Techna Institute for the Advancement of Technology for Health on ‘˜‡„‡”͡ǡ͚͙͙͘Ǥ‡†„›”Ǥƒ˜‹† ƒơ”ƒ›ǡ‡ Šƒ‹• a new research institute focused on addressing unmet clinical needs through the advancement of novel technologies. It will serve as a vital bridge between clinicians and researchers. Techna is funded in part by The Princess Margaret Hospital Foundation (PMHF) and a generous donation from Carlo Fidani.

The Institute will encourage collaboration through the shared use of multiple existing facilities at UHN, including the Spatio-Temporal Targeting and ’Ž‹Ƥ ƒ–‹‘‘ˆƒ†‹ƒ–‹‘‡•’‘•‡ ‘˜ƒ–‹‘ Centre and the Guided Therapeutics program. With (L-R) Paul Alofs (President and CEO, PMHF) , Dr. Christopher Paige, over $100M in available resources, Techna will create ƒ”Ž‘ ‹†ƒ‹ǡ”•Ǥƒ˜‹† ƒơ”ƒ›ǡƒ”› ‘•’‘†ƒ”‘™‹ œȋ”‘‰”ƒ‡†‹ ƒŽ new and exciting research partnerships while bringing Director, PMH Cancer Program) and Robert Bell at Techna launch innovative technologies to patient care.

UHN Radiation Medicine Tools Licensed to RaySearch Laboratories

HN has signed a licensing agreement with RaySearch ULaboratories regarding deformable image registration technology developed at PMH. The agreement, licensed through UHN’s Technology Development & ‘‡” ‹ƒŽ‹œƒ–‹‘ȋȌƥ ‡ǡƒŽŽ‘™•ˆ‘”–Š‡‹–‡‰”ƒ–‹‘ of the research software “Morfeus” into RaySearch’s commercial radiation treatment planning system.

Developed by a team of scientists and physicians led by OCI Scientist Dr. Kristy Brock, Morfeus is a program that tracks how a dose of radiation is delivered to a patient, taking into account physiological changes in the patient over the course ‘ˆ–”‡ƒ–‡–ǤŠ‹•‹ˆ‘”ƒ–‹‘™‹ŽŽ„‡—•‡†–‘”‡Ƥ‡”ƒ†‹ƒ–‹‘ –”‡ƒ–‡–ƒ†Š‡Ž’”‡†— ‡–Š‡”‹•ˆ‘”•‹†‡‡ơ‡ –•Ǥ

Dr. Kristy Brock 12 Charles Tator Honoured with Global Impact Award

HN’s Global Impact Award was presented to UTWRI’s Dr. Charles Tator in recognition of his pioneering research in spinal cord injury and international leadership in the prevention of head injury.

”Ǥƒ–‘”ǯ• ‘–”‹„—–‹‘•–‘–Š‡Ƥ‡Ž†‹ Ž—†‡ †‡˜‡Ž‘’‹‰–Š‡Ƥ”•–ƒ —–‡•’‹ƒŽ ‘”†‹Œ—”›—‹– in Canada, demonstrating that post-traumatic ischemia is a major secondary injury mechanism and inventing the inclined plane technique of functional assessment. His research has expanded to sports and recreational injuries to the brain and spine with the development of the Krembil Neuroscience Centre Sports Concussion Project.

UHN and CFL Join Forces to Form Concussion Research Awareness Program

r. Charles Tator, in conjunction with the Canadian DFootball League (CFL), has announced the development of the Krembil Neuroscience Centre Sports Concussion Project. This program will evaluate the link between repeated concussions and deterioration of brain function in athletes and non- athletes and develop a concussion safety education program.

—””‡–Ž›ǡƤ˜‡ˆ‘”‡” ’Žƒ›‡”•ƒ”‡’Žƒ‹‰–‘ donate their brains to the study. Dr. Tator comments, “I think it’s a thrill when someone of their stature says, ‘I believe in your project, and when the time comes, you can have my brain.’ They are putting their ‘Ƥ†‡ ‡‹—•–‘Ƥ†–Š‡ƒ•™‡”•Ǥdz

Dr. Charles Tator

13 Gang Zheng Named UHN Inventor of the Year

HN’s 2010 Inventor of the Year Award was Upresented to OCI’s Dr. Gang Zheng. This award, sponsored through UHN and TDC, is presented to a UHN researcher who has made an outstanding and inventive contribution to patient-oriented biomedical research.

Dr. Zheng’s invention focused on the creation of a unique organic nanoparticle delivery platform capable of transporting cancer therapeutics directly to tumours. This technology could potentially ”‡†— ‡•‹†‡‡ơ‡ –•‹’ƒ–‹‡–•†—‡–‘–Š‡‘–‘š‹  nature of the nanocarriers and the targeted delivery of the drugs. UHN, in collaboration with the Ontario Institute for Cancer Research, has recently formed a Toronto-based biotechnology company called DLVR Therapeutics Inc. to rapidly advance the commercialization of this technology for clinical use.

New CIHR Funding for Nanomedicine Research

r. Gang Zheng and colleagues were awarded Dnew funding to advance nanomedicine research from the Canadian Institutes of Health Research’s Emerging Team Grant: Regenerative Medicine and Nanomedicine program. The team will receive ͚͆Ǥ͚͛‘˜‡”Ƥ˜‡›‡ƒ”•–‘•—’’‘”––Š‡‘’‡”ƒ–‹‘‘ˆ the project.

The research project, entitled “Nanotechnology- enabled image-guided interventions in vascular and lung diseases”, will translate innovations in nanotechnology into commercially viable, clinical trial-ready products by focusing on developing nanotechnology-enabled image-guided treatments for lung cancer and vascular diseases. The Dr. Gang Zheng multidisciplinary research team includes UHN co-investigators Drs. Brian Wilson, David Hwang, Ren-Ke Li, Kazuhiro Yasufuku and the University of Toronto’s Dr. Warren Chan.

14 McEwen Centre Launches Stem Cell City

—‡͙͝ǡ͚͙͙͘ƒ”‡†–Š‡‹ Ǧ‘ơ‘ˆ–‡‡ŽŽ JCity, an initiative by UHN’s McEwen Centre for Regenerative Medicine to raise awareness about stem cell research and to allow people to articulate their support of using regenerative medicine to defeat the major diseases of our time. The Centre’s Director, Dr. Gordon Keller, and co-founders Cheryl and Rob McEwen announced the launch of this exciting project. They encouraged everyone to join ‹–Š‡‹” ”—•ƒ†‡–‘Ƥ‰Š–†‹•‡ƒ•‡–Š”‘—‰Š–Š‡•—’’‘”– of regenerative medicine.

Join Stem Cell City.

(L-R) Dr. Gordon Keller, Robert Klein (Chair, Governing Board of the California Institute for Regenerative Medicine), Dalton McGuinty (Premier of Ontario), Dr. Eric Hoskins (Ontario Minister of Children and Youth Services) and Robert McEwen at Stem Cell City launch

 ǯ•‡™ƥ ‡‘ˆ Research Trainees

 —Ž›͙͠ǡ͚͙͙͘ǡ Žƒ— Š‡†–Š‡ƥ ‡‘ˆ‡•‡ƒ” Š OTrainees (ORT) to help enhance support for the development of students and postdoctoral fellows. Leading this initiative is Dr. Linda Penn, who was appointed as the ORT Director.

ORT’s mission is to showcase UHN’s strong research environment; represent, support and enhance the quality of research training within UHN; facilitate information exchange and interaction amongst trainees and help trainees obtain Dr. Linda Penn external funding.

UHN Announces Joint Venture with CPDC

HN and the Centre for Probe Development and Commercialization (CPDC) announced a Ujoint venture—the Canadian Molecular Imaging Probe Consortium (CanProbe)—to advance the development and use of medical isotopes for diagnosing and treating cancer and other serious diseases. CanProbe will establish a new research centre in Toronto, supplying molecular ‹ƒ‰‹‰’”‘„‡•–‘•—’’‘”–”‡•‡ƒ” Šƒ† Ž‹‹ ƒŽ‹ƒ‰‹‰’”‘‰”ƒ•ˆ‘” ǦƒƥŽ‹ƒ–‡†Š‘•’‹–ƒŽ•Ǥ Š‡‡–”‡™‹ŽŽƒŽ•‘‹–”‘†— ‡‡™‹ƒ‰‹‰’”‘„‡•–‘–ƒ”‹‘–Š”‘—‰Š‹–•‘™”‡•‡ƒ” Š‡ơ‘”–• and manufacture probes that are used by the global nuclear medicine community.

15 Bringing Innovative Cancer Therapeutics to Canadians

he Princess Margaret Hospital Phase II Consortium T(PMHC) has renewed its third contract through the National Institutes of Health to design, develop and conduct early phase clinical trials of agents, sponsored through the National Cancer Institute’s Cancer Therapy Evaluation Program. PMHC, led by Dr. Amit Oza, will continue to conduct innovative clinical trials with promising combination therapies that are pivotal for drug development and enable PMH’s clinical trials program to provide oncology patients with rapid access to novel anti-cancer therapies. As a contract holder since 2001 and the only non-US site funded, PMHC has accrued more than 1,400 patients on early phase clinical trials with participating sites in British Columbia, Alberta and Ontario. (L-R) Drs. Amit Oza, Lillian Siu and Malcolm Moore

OCI/PMH Selected as Member Site in Cancer Immunotherapy Trials

CI/PMH has been selected as one of 27 institutions, and the Oonly institution outside of the US, to participate in the Cancer Immunotherapy Trials Network (CITN), funded by the National Cancer Institute. Led by Dr. Pamela Ohashi, UHN will conduct phase I and II clinical trials in the area of cancer immunotherapy and will focus on using new agents and approaches to improve the ability ‘ˆ–Š‡’ƒ–‹‡–•ǯ‘™‹—‡•›•–‡•–‘Ƥ‰Š– ƒ ‡”Ǥƒ”–‹ ‹’ƒ–‹‘ in the CITN will strengthen UHN’s position globally as an emerging centre for immune therapy.

Landmark Donation from Lundbeck Canada to TWRI

undbeck Canada has made a landmark Ldonation of $2.7M to support pioneering research to identify biomarkers that will ‡Šƒ ‡–Š‡–”‡ƒ–‡–‘ˆ’ƒ–‹‡–••—ơ‡”‹‰ from depression and bipolar disorder.

The donation will help establish the Canadian Depression Biomarker Network, a Canada-wide study led by Dr. Sidney Kennedy, UHN’s Psychiatrist-in-Chief. The Network will use clinical and molecular data to create personalized predictions about treatment response and to identify and develop new therapeutic targets. (L-R) Marie Gagné, Gleb Filippov, Dr. Susan Rotzinger, Noam Ship, Stuart McBurnie 16 and Dr. Sidney Kennedy Constructing the Future of Research Innovation at TWH

his past year saw the completion of Phase 1 and 2 Tdemolition as part of the ongoing construction of the Krembil Discovery Centre at TWH. The Centre, whose construction began in 2010, will be a 325,000 square foot ˆƒ ‹Ž‹–›•’ƒ‹‰‹‡ƪ‘‘”•ǡ‹ Ž—†‹‰͙͘͝ǡ͘͘͘•“—ƒ”‡ˆ‡‡– of laboratory space.

The state-of-the-art research space will house world renowned research programs in arthritis and rheumatism, autoimmune diseases, spinal cord injury, stroke, Parkinson’s disease, epilepsy, Alzheimer’s disease, brain tumours and aneurysms, pain disorders, eye diseases and orthopedics. The Centre is scheduled to open its doors in 2013. An architectural rendering of the Krembil Discovery Centre

(Front row, L-R) Drs. Patricia Shaw, Michael Reedijk and Pamela Ohashi; (Middle row, L-R) Drs. Wey-Liang Leong, Alexandra Easson and David McCready; (Back row, L-R) Jessica Nie and Dr. Danny Ghazarian

TWRI Captures New Funding from MRI

he Ontario Ministry of Research and Innovation (MRI) has awarded TWRI’s Dr. TMichael Tymianski $1.4M in new funding from the Ontario Research Fund– Research Excellence Program, Round 5 competition. Financial support for the project “TRPM7 Inhibitors for the Treatment of Stroke and Myocardial Ischemia” will be used to develop drugs targeting TRPM7, a protein implicated in the treatment of cellular damage arising from stroke, heart attack and retinal disorders.

Dr. Michael Tymianski Honour Roll Selected achievements of UHN Researchers from 2010-2011

Bernard Cummings MB, ChB, FRCPC

2011 ASTRO Gold Medal, American Society for Radiation Oncology Mitsuhiko Ikura PhD

2010 Robert L. Noble Prize, Canadian Cancer Society

Eleanor Fish PhD

2010 Seymour and Vivian Milstein Award for Excellence in Interferon and Cytokine Research, Michael Jewett International Society for Interferon and MD, FRCSC Cytokine Research 2011 Distinguished Contribution Award, American Urological Association; 2011 Society of Urologic Oncology Medal, Society of Urologic Oncology

Richard Hill PhD

2011 Henry S. Kaplan Distinguished Scientist Award, International Association for Radiation Anthony Lang Research MD, FRCPC

ƥ ‡”ǡ Order of Canada; Fellow, Royal Society of Canada; Fellow, Canadian Academy of Health Sciences 18 Charles Tator MD, PhD, FRCSC, FACS

2011 ASIA Lifetime Achievement Award, Ren-Ke Li American Spinal Injury Association MD, PhD

Fellow, Canadian Academy of Health Sciences

Bradly Wouters BEng, PhD

Klaas Breur Gold Medal Award, European Society for Therapeutic Carol-Anne Moulton Radiology and Oncology MD, FRCSC, PhD

Early Researcher Award, Ontario Ministry of Research and Innovation

Camilla Zimmermann MD, PhD, FRCPC

2010 William E. Rawls Prize, Canadian Cancer Society Peter Singer MD, MPH, FRCPC, FRSC

ƥ ‡”ǡ Order of Canada

19 20 Raising a Glass to Neuroscience Research

Toronto General & Western Hospital Foundation Grand Cru Culinary Wine Festival

arly in October 2010, 350 strategies through innovative in private homes throughout the Econnoisseurs and gourmands research. Its research component is city. Each chef who participated joined some of the city’s most aimed at advancing experimental generously donated their time, ’”‘‹‡–• ‹‡–‹Ƥ ‹†•ˆ‘”–Š‡ discoveries through preclinical and preparing sensational tasting 6th Annual Grand Cru Culinary Wine clinical trials to bring promising menus paired with exceptional Festival, Toronto’s premier wine new therapies to individuals with wines provided by a number of and food event. The event raised spinal cord injuries. Established in international wine estates. In $800,000 to support basic research 1994, the program is recognized addition to Dr. Fehlings, many within the Spinal Program at the as a Centre of Excellence in Spinal prominent UHN researchers Krembil Neuroscience Centre, and Spinal Cord Injury Care by attended the event including Drs. led by Dr. Michael Fehlings, and the Christopher and Dana Reeve Michael Tymianski, Andres Lozano, research infrastructure at TGRI and Foundation. Shaf Keshavjee and Vivek Rao. TWRI. The 2010 Grand Cru event featured ˜‡”‹–•Ƥ”•–•‹š›‡ƒ”•ǡ–Š‡Grand The Spinal Program provides local and international culinary Cru Culinary Wine Festival has comprehensive treatment for talent, including celebrity chefs raised more than $8.2M for various patients with spinal disorders and Mark McEwan and Victor Barry and programs at UHN. spinal cord injury, and accelerates some of the world’s foremost wine the discovery of novel treatment producers. The event was hosted

(L-R) Armando Fumanelli (Cantine Marchesi Fumanelli Winery), Cheryl McEwen, Chef Victor Barry (Splendido), Dr. Michael Fehlings, Dr. Shaf Keshavjee and Robert McEwen

DzŠ‹•‡˜‡– ‘–‹—‡•–‘ƒ‰‡— ŠŽ‹‡ƒƤ‡™‹‡Ǥƒ Š›‡ƒ”™‡ set even more aggressive goals than the year before, in terms of the projects we raise funds for, and each year, we meet them.” - Event Chair & Founder Todd Halpern Playing Canada’s Game for a Cure

(L-R) Scott Morrison, Don Cherry, Peter Goodhand, Paul Alofs and Tyler McGregor Princess Margaret Hospital Foundation Road Hockey to Conquer Cancer

he inaugural Road Hockey to Conquer Cancer event muscles with massages and enjoyed interactive games Twas held at Ontario Place on October 1, 2011, with and live music. More than 70 celebrities played as more than 1500 players and 200 teams participating, honourary captains alongside the participants, including raising over $2.4M for cancer research. The event, former NHLers Jeremy Roenick and Bryan Trottier, hosted by PMHF and the Canadian Cancer Society (CCS), Ƥ‰—”‡•ƒ–‹‰ Šƒ’‹‘Ž‹œƒ„‡–ŠƒŽ‡›ǡŽ›’‹ ‰‘Ž† set a world record for a road hockey event fundraiser. medalists Alexandre Bilodeau and Adam van Koeverden, and a number of musicians and media personalities. The day began just after sunrise with a stirring opening ceremony that included hockey icon Don Cherry; UHN An emotional closing ceremony, led by Steve Merker President and CEO, Dr. Robert Bell; PMHF President (PMHF) and James Duthie (TSN), included Dr. Peter and CEO, Paul Alofs; CCS President and CEO, Peter Ferguson, head of the Sarcoma Site at PMH, who spoke Goodhand; and Executive Producer of Hockey for on behalf of the doctors participating in the ceremony. Rogers Sportsnet, Scott Morrison. Tyler McGregor, an elite hockey player before losing Š‹•Ž‡‰–‘ ƒ ‡”ǡ‰ƒ˜‡ƒˆ‡™ƤƒŽ™‘”†•ƒ„‘—–™Š›–Š‹• ƒ Š‘ˆ–Š‡–‡ƒ•’Žƒ›‡†Ƥ˜‡‰ƒ‡•–Š”‘—‰Š‘—––Š‡ event was important to him and to all the young men course of the day and, in between, nursed aching and women who face a diagnosis of cancer.

22 Research on the Runway

Arthritis Research Foundation Kick Up Your Heels

ƒ›ǡ ǯ•”–Š”‹–‹•‡•‡ƒ” Š ‘—†ƒ–‹‘Š‡Ž†‹–•Ƥ”•– Iannual Kick Up Your Heels event, a shoe- and fashion-themed ˆ—†”ƒ‹•‡”–‘„‡‡Ƥ–ƒ”–Š”‹–‹•”‡•‡ƒ” Šƒ– ǤŠ‡‘ ƒ•‹‘ attracted over 200 guests to the Koerner Hall at the Royal Conservatory of Music in Toronto for an evening of food and wine tastings, live music and a fashion show.

“Kick Up Your Heels was born when we decided to update our annual fashion show event. We wanted to create a unique evening, still attractive to our predominantly female guests, featuring upscale fashion with a twist,” explains Arthritis Research Foundation Special Events Coordinator Gillian Williams.

Headlining the evening was a fashion show featuring spring dresses and shoes modelled by local Toronto celebrities and Arthritis & Autoimmunity Research Centre (AARC) researchers, including Director Dr. Eleanor Fish and members Drs. Mark Erwin and Monique Gignac. Other highlights included a wine and shoe pairing, live music from Royal Conservatory artists and a rare wine bottle auction. Attendees included CP24 anchor Farah Nasser, CBC radio host Mary Ito and AARC members Drs. Dafna Gladman and Murray Urowitz.

The evening, now planned as the Arthritis Research Foundation’s annual spring fundraising event, proved to be a great success. “Our attendees loved the concept! The inaugural night in the soaring glass lobby of Koerner Hall was an even bigger success than we ever imagined,” adds Ms. Williams.

The event raised over $60,000 to help support research into the causes, treatment and cure of arthritis and autoimmune diseases. Explains Arthritis Research Foundation Executive ‹”‡ –‘”ƒ˜‡”‘™–‡ǡDzŠ‹•”‡•‡ƒ” Š‹• ”‹–‹ ƒŽˆ‘”Ƥ†‹‰ ‘”‡‰”‘—†Ǧ„”‡ƒ‹‰ƒ†‡ơ‡ –‹˜‡•‘Ž—–‹‘•ˆ‘”–Š‡‘˜‡” ͜Ǥ͝‹ŽŽ‹‘ƒƒ†‹ƒ••—ơ‡”‹‰ˆ”‘–Š‡•‡†‡„‹Ž‹–ƒ–‹‰ conditions.”

AARC Director Dr. Eleanor Fish 23 modelled shoes at the event RESEARCH

UHN’s principal investigators undertake a full spectrum of biomedical research to gain understanding about life to improve Š‡ƒŽ–ŠǤŠ‡•‡Ƥ˜‡–Š‡‡•”‡’”‡•‡––Š‡”‡•‡ƒ” Š’”‹‘”‹–›ƒ”‡ƒ•–Šƒ– will help guide UHN to becoming the Research Hospital of the Future.

Mechanisms of Disease encompasses the basic research that uncovers new knowledge of the underlying foundations of phenomena.

Experimental Therapeutics comprises the clinical research cluster at UHN, ™Š‹ Š•‡‡•–‘—†‡”•–ƒ†ƒ†‹’”‘˜‡–”‡ƒ–‡–ƒ†–‘†‡˜‡Ž‘’Ƥ”•–Ǧ‹ǦŠ—ƒ clinical trials.

Medical Technology includes a wide range of health care products that, in one form or another, are used to diagnose, monitor or treat diseases or conditions –Šƒ–ƒơ‡ –Š—ƒ•Ǥ

Informatics ‹•†‡Ƥ‡†ƒ•–Š‡• ‹‡ ‡‘ˆ‹ˆ‘”ƒ–‹‘ ‘ŽŽ‡ –‹‘ǡ’”‘ ‡••‹‰ƒ† engineering of information systems. It studies the structure, behaviour and interactions of systems that store, process, access and communicate information, as well as clinical guidelines and formal medical terminologies in health care systems.

Health Services Research is a multidisciplinary and inter-professional Ƥ‡Ž†‘ˆ‹“—‹”›ǡ„‘–Š„ƒ•‹ ƒ†ƒ’’Ž‹‡†ǡ–Šƒ–‡šƒ‹‡•–Š‡—•‡ǡ ‘•–ǡ“—ƒŽ‹–›ǡ ƒ ‡••‹„‹Ž‹–›ǡ†‡Ž‹˜‡”›ǡ‘”‰ƒ‹œƒ–‹‘ǡƤƒ ‹‰ƒ†‘—– ‘‡•‘ˆŠ‡ƒŽ–Š ƒ”‡ services.

2624 MECHANISMS OF DISEASE

Stem Cells that Control Human Blood Production

ematopoietic stem cells (HSCs) are solely responsible Hfor lifelong blood production, but they are very rare and †‹ƥ —Ž––‘‹•‘Žƒ–‡Ǥ‡•‡ƒ” Š‡”•ƒ– ǡŽ‡†„› ǯ•”Ǥ ‘Š ‹ ǡ‹†‡–‹Ƥ‡†ƒ‡–Š‘†–‘‹•‘Žƒ–‡•‹‰Ž‡ • ƒ’ƒ„Ž‡‘ˆ developing into multiple cell types comprising a functional blood system.

•‹‰ƒ–‡ Š‹“—‡‘™ƒ•ƪ‘™ ›–‘‡–”›ǡƒ’”‘ ‡••–Šƒ– discriminates cells based on cell surface proteins, the team isolated cells expressing a protein called CD49f (CD49f+ cells). They found that a single CD49f+ cell was able to self-renew, function in the body over the long term and was capable of developing into all the functional cell types of the blood system.

Š‡•‡Ƥ†‹‰•ƒ”‡ƒƒŒ‘”•–‡’–‘™ƒ”†•”‡ƒŽ‹œ‹‰–Š‡’”‘‹•‡ of regenerative medicine for patients. “This discovery means that we have an increasingly detailed road map of how human blood develops,” says Dr. Dick. “Stem cell scientists can now start characterizing the core properties of these cells and develop better methods to harness the power of HSCs for clinical transplantation.”

Notta F et al. Science. 2011 Jul. Research supported by the Canadian Institutes of Health Research, the Terry Fox Foundation, Genome Canada through the Ontario Genomics Institute, the Ontario Institute for Cancer Research, the Ontario Ministry of Health and Long-Term Care, the Canada Research Chairs Program, the McEwen Centre for Regenerative Medicine and The Princess Margaret Hospital Foundation.

Watch a video of Dr. Dick discussing these findings.

Faiyaz Notta and Dr. John Dick The Physiology of Synaptic Transmission ommunication bbetween neurons in forf Cav2 channelshlh at the Cthe brain occurs at synapses by the nerve terminal. Dr. Stanley impulse-triggered release of chemical explains, “Our results carry transmitters at the nerve terminal. weight because a dramatic Calcium ions (Ca2+) entering through improvement in recording voltage-gated calcium channels (CavȎ methods allowed us to trigger synaptic vesicles (that package measure single calcium transmitters) to fuse and discharge channel currents with their contents. Curious as to why the physiological Ca2+ Cav2 family, with its reported low concentrations.” Ca2+ transport capacity, predominates at nerve terminals, the laboratory This work also provide of TWRI Senior Scientist Dr. Elise support for Dr. Stanley’s Stanley—including trainees Alexander ’”‡˜‹‘—•Ƥ†‹‰•–Šƒ– ‡„‡”ǡ ‹‘ƒ‘‰ǡƒ††‡Ž‡—ơ‘”†Ǣ synaptic vesicle fusion can collaborators Drs. Lyanne Schlichter be triggered by a single, Dr. Elise Stanley, Fiona Wong and Qi Li and Victor Matveev; and assisted by nearby calcium channel. technicians Qi Li and Xiaoping Zhu—re- Because neurotransmitter Weber AM et al. Nat Neurosci. 2010 Nov. examined the established Cav1 > Cav2 release is involved in virtually every Research supported by the Canadian Institutes > Cav3 hierarchy originally determined aspect of nervous system function, of Health Research, the Canada Research with non-physiological conditions. these results have a major impact on Chairs Program, the Anne and Max Tanenbaum the understanding of normal brain Chair in Molecular Neuroscience, the Ontario Contrary to ‘textbook fact’, the results processing, as well as a broad variety of Graduate Scholarship and the National Science Foundation. demonstrated a Cav2.2 > Cav1 > Cav3 nervous system disorders. hierarchy and explain the preference

New Insights into Blood Glucose Regulation

TGRI study by Dr. Tony Lam and decreased blood glucose levels. These Ahis team revealed new information results indicate that PKC is involved about nutrient sensing—the ability of in nutrient sensing in the gut thereby cells to recognize and respond to energy helping to regulate normal blood glucose substrates like glucose. They examined levels. whether protein kinase C (PKC), an ‡œ›‡™‹–Šƒ›†‹ơ‡”‡–ˆ— –‹‘• Dr. Lam explains, “This reveals a new role located in the lining of the gut, plays a ˆ‘”†—‘†‡ƒŽǦɁ‹‰Ž— ‘•‡”‡‰—Žƒ–‹‘ role in triggering important signals to the and maintaining nutrient balance. We brain and liver for maintaining healthy believe that activation of this system in blood glucose levels. the duodenum could help lower blood glucose levels in diabetes and obesity.” By inhibiting the action of PKC in the †—‘†‡—Ȅ–Š‡Ƥ”•–•‡ –‹‘‘ˆ–Š‡•ƒŽŽ Kokorovic A et al. Gastroenterology. 2011 Jun. intestine—the team found that there was Research supported by the Canadian Institutes ƒ•‹‰‹Ƥ ƒ–‹ ”‡ƒ•‡‹„Ž‘‘†‰Ž— ‘•‡ of Health Research, the Canada Research levels. Conversely, activation of a form Chairs Program and the John Kitson McIvor ‘ˆȋǦɁȌ‹–Š‡†—‘†‡—Ž‡†–‘ Chair in Diabetes Research.

28 Dr. Tony Lam EXPERIMENTAL THERAPEUTICS

(Front row, L-R) Drs. Marcelo Cypel, Mingyao Liu and Shaf Keshavjee and some members of the Latner Thoracic Laboratories team A System Developed to Improve Donor Lungs

TGRI research team has shown in a clinical trial, for provide more lungs with predictable, safer outcomes after A–Š‡Ƥ”•––‹‡ǡ–Šƒ––Š‡‘”‘–‘ —‰‡”ˆ—•‹‘ –”ƒ•’Žƒ–ƒ–‹‘ǡdz•ƒ›•”Ǥƒ” ‡Ž‘›’‡ŽǡƤ”•–ƒ—–Š‘”‘ˆ–Š‡ ›•–‡ ƒ•ƒˆ‡Ž›ƒ†‡ơ‡ –‹˜‡Ž›–”‡ƒ–ǡ”‡Ǧƒ••‡••ƒ†‹’”‘˜‡ study. the function of high-risk donor lungs so that they can be successfully transplanted into patients. This technique could “This heralds a new era in transplantation when we can •‹‰‹Ƥ ƒ–Ž›‡š’ƒ†–Š‡†‘‘”‘”‰ƒ’‘‘Žƒ†‹’”‘˜‡ predict how well the organ functions before using it,” adds Dr. outcomes after transplantation. Keshavjee. “We can help the organ heal itself, and ultimately, we can use the Toronto XVIVO System as a platform to Led by Dr. Shaf Keshavjee, the team found that using high- engineer ‘super organs’ for transplantation.” risk donor lungs, which were improved and re-tested in the Toronto XVIVO System before surgery, led to results Cypel M et al. N Engl J Med. 2011 Apr. Research supported by Vitrolife comparable to those using conventional donor lungs. and the McEwen Centre for Regenerative Medicine. “Donor lungs previously thought to be unusable can now be used for transplantation with excellent outcomes. This will Watch how the XVIVO system works.

27 Stimulating Treatment Techniques for Alzheimer’s Disease

team of researchers at TWRI, led by Dr. Andres A‘œƒ‘ǡ ‘’Ž‡–‡†–Š‡Ƥ”•–—Ž–‹Ǧ’ƒ–‹‡– ’Šƒ•‡ –”‹ƒŽ‹˜‡•–‹‰ƒ–‹‰–Š‡‡ơ‡ –•‘ˆ†‡‡’„”ƒ‹ stimulation (DBS) for the treatment of patients with mild Alzheimer’s disease (AD). DBS involves placing ‡Ž‡ –”‘†‡•ƒ–•’‡ ‹Ƥ •‹–‡•‹–Š‡„”ƒ‹–‘†‡Ž‹˜‡” continuous stimulation from an implanted generator.

Explains Dr. Lozano, “We have found evidence Drs. Andres Lozano, David Tang Wai, Mary Pat McAndrews and Adrian Laxton showing how DBS to a region of the brain known as the fornix may possibly improve memory and/or slow the rate •ƒˆ‡–›ƒ†„‹‘Ž‘‰‹ ƒŽ‡ơ‡ –•‘ˆ–Š‡’”‘ ‡†—”‡ƒ”‡•—ƥ ‹‡–Ž› of cognitive decline.” compelling to warrant a phase II clinical trial to better understand if DBS may be a potential therapeutic option for Using state-of-the-art imaging methods, the team found that patients with AD.” DBS improved brain activity in areas that were dysfunctional. Š‡•‡‡ơ‡ –•™‡”‡ƒ‹–ƒ‹‡†ˆ‘”—’–‘ƒ›‡ƒ”ƒˆ–‡”–Š‡•–—†›Ǥ Laxton AW et al. Ann Neurol. 2010 Aug. Research supported by the Neurosurgical Research and Education Foundation, the Dana Foundation, the Canada Research Chairs Program, the RR Tasker Chair in Dz‘ơ‡”•–Š‡’‘••‹„‹Ž‹–›‘ˆ‘†—Žƒ–‹‰„”ƒ‹ ‹” —‹–•‹ƒ Stereotactic and Functional Neurosurgery and the Krembil Neuroscience adjustable and reversible fashion,” says Dr. Lozano. “The Discovery Fund.

New Surgical Procedure Reverses Loss of Brain Matter

Š‡„Ž‘‘†ƪ‘™‹•”‡†— ‡†–‘ƒ”‡ƒ•‘ˆ–Š‡„”ƒ‹ƒ•ƒ”‡•—Ž– of diseased blood vessels, there is a progressive loss of tissue through a process known as cortical thinning. Cortical thinning ƒƒơ‡ – ‘‰‹–‹˜‡ˆ— –‹‘ǡ‹ ”‡ƒ•‡”‹•‘ˆ•–”‘‡ƒ†Ž‡ƒ†–‘ the development of neurodegenerative disorders. The group examined patients who had undergone cranial bypass surgery –‘”‡•–‘”‡„Ž‘‘†ƪ‘™ƒ†‡ƒ•—”‡† Šƒ‰‡•‹ ‘”–‹ ƒŽ˜‘Ž—‡ by magnetic resonance imaging. Eleven months after surgery, ƒ͝Ǥ͙ά‹ ”‡ƒ•‡‹ ‘”–‹ ƒŽ–Š‹ ‡••™ƒ•‘„•‡”˜‡†‹ƒơ‡ –‡† ƒ”‡ƒ•ǡ”‡˜‡”•‹‰–Š‡†ƒƒ‰‹‰‡ơ‡ –•‘ˆ†‡ ”‡ƒ•‡†„Ž‘‘†ƪ‘™Ǥ

Explains study lead Dr. Michael Tymianski, “The re-growth of brain tissue has only been observed in an extremely limited —„‡”‘ˆ ‹” —•–ƒ ‡•ǤŠ‡•‡Ƥ†‹‰•ƒ”‡‹’‘”–ƒ– Dr. Michael Tymianski because one of the most prevalent health issues facing our esearchers at TWRI have initiated the restoration of lost population is chronic cerebrovascular disease.” Rbrain tissue through brain bypass surgery in patients where „Ž‘‘†ƪ‘™–‘–Š‡„”ƒ‹‹•‹’ƒ‹”‡†„› ‡”‡„”‘˜ƒ• —Žƒ”†‹•‡ƒ•‡Ǥ Fierstra J et al. Stroke. 2011 Apr. Research supported by the Chair Fund Š‹•‹•–Š‡Ƥ”•–•–—†›–‘†‡‘•–”ƒ–‡–Šƒ–ƒ•—”‰‹ ƒŽ–”‡ƒ–‡– of UHN’s Neurovascular Therapeutics Program and the Ontario Research can restore lost brain tissue. Fund Brain Consortium Grant.

28 (L-R) Alisha Elford, Dr. Kiichi Murakami, Michael Pniak, Jessica Nie and Dr. Pamela Ohashi Using T Cells to Combat Cancer

cells are cells of the immune system States and Israel have found that this Dz‡ƒ”‡–Š‡Ƥ”•–‰”‘—’‹ƒƒ†ƒ–‘ T–Šƒ–•’‡ ‹Ƥ ƒŽŽ›”‡ ‘‰‹œ‡ƒ†–ƒ”‰‡– ƒ’’”‘ƒ ŠŠƒ•„‡‡Ƥ–•ˆ‘”’ƒ–‹‡–•™‹–Š establish this expertise. The design foreign particles in the body. While metastatic melanoma. of clinical protocols using TILs at our they have been found within tumours institution is currently underway,” says of cancer patients, T cells are unable to OCI Senior Scientist Dr. Pamela Dr. Ohashi. “We’ve assembled a team ‘—–ƒ•—ƥ ‹‡–‹—‡”‡•’‘•‡–‘ Ohashi has published a study laying including surgeons, medical oncologists prevent tumour growth and progression. the groundwork for developing clinical and pathologists to advance immune ‡ ‡–‡ơ‘”–•Šƒ˜‡„‡‡ƒ‹‡†ƒ–‘‡ trials using TILs in Canada. Using 40 therapy at UHN.” type of immune therapy called adoptive tissue samples derived from melanoma T cell therapy, which involves extracting patients, her team developed a robust Nguyen LT et al. PLoS One. 2010 Nov. the T cells found in the tumour (tumour protocol to isolate and expand TILs. The Research supported by the Campbell Family Institute for Breast Cancer Research, the ‹ƤŽ–”ƒ–‹‰Ž›’Š‘ ›–‡•ǡ •Ȍƒ† cells were grown to amounts required Canadian Breast Cancer Research Alliance, expanding the population of these cells for therapeutic administration and were the Ontario Institute for Cancer Research, the before re-infusing them back into the ‡ơ‡ –‹˜‡‹–Š‡‹”ƒ„‹Ž‹–›–‘‹ŽŽ ƒ ‡”‘—• Canada Research Chairs Program and The patient. Studies performed in the United cells. Princess Margaret Hospital Foundation.

29 MEDICAL TECHNOLOGY

(L-R) Jon Lovell, Dr. Gang Zheng, Thomas MacDonald and Cheng Jin Organic Nanoparticles for Targeting and Treating Cancer

n OCI team, led by Dr. Gang of 60°C, destroying the tumour. The options previously unavailable. We are AZheng, has created an organic, nanoparticle can also be used for excited by the possibilities for its use nontoxic and biodegradable photoacoustic imaging—combining in the clinic.” nanoparticle—a minute molecule with light and sound to produce a high- novel properties—that uses light and ”‡•‘Ž—–‹‘‹ƒ‰‡–‘Š‡Ž’Ƥ†ƒ† Lovell JF et al. Nat Mater. 2011 Mar. heat to deliver drugs and treat cancer. target tumours. Research supported by the Ontario Institute for Cancer Research, the Canadian Dr. Zheng’s team combined two “This new nanoparticle has a simple Cancer Society, the Natural Sciences and Engineering Research Council, the Canadian naturally occurring molecules structure, versatile function and Institutes of Health Research, the Joey and (chlorophyll and lipids) to create a unprecedented safety,” explains Toby Tanenbaum/Brazilian Ball Chair in unique nanoparticle that targets Dr. Zheng. “There are many Prostate Cancer Research, the Campbell tumour cells and absorbs light. The nanoparticles out there but this one Family Institute for Cancer Research, the group then used a laser to rapidly heat is the complete package for various Ontario Ministry of Health and Long-Term the nanoparticles to a temperature types of cancer imaging and treatment Care and The Princess Margaret Hospital Foundation.

30 Making CT Scanning Safer for Patient Use

led to faster scanning and better image quality resulting in its more frequent use in the clinic. However, the increased use of CT scanning has raised concern regarding the associated radiation exposure delivered to patients.

CT scanning produces a single three-dimensional image from a series of two-dimensional x-ray images (radiographs) taken at various perspectives about a patient. The team tested ƒ’”‘’‘•‡†ƒ’’”‘ƒ Šǡ ƒŽŽ‡†ƪ—‡ ‡Ƥ‡Ž†‘†—Žƒ–‡† ȋ Ȍǡ–Šƒ–‘†‹Ƥ‡•Š‘™–Š‡šǦ”ƒ›„‡ƒ‹•†‡Ž‹˜‡”‡††—”‹‰ scanning. The study showed that FFMCT could potentially deliver quality images of target areas of interest with radiation dose reductions ranging from 39-52%.

DzŠ‹•ƒ’’”‘ƒ Šƒƒ‰‡•–Š‡–”ƒ†‡‘ơ„‡–™‡‡‹ƒ‰‡“—ƒŽ‹–› ”Ǥƒ˜‹† ƒơ”ƒ›ƒ†–‡˜‡ƒ”–‘Žƒ ƒ††‘•‡‘•–‡ơ‡ –‹˜‡Ž›ǡdz•–ƒ–‡•”Ǥ ƒơ”ƒ›ǤDz  could have a positive impact on the utility and safety of CT ‡ ‡–Ƥ†‹‰•ˆ”‘ ǯ•”Ǥƒ˜‹† ƒơ”ƒ›ƒ†Š‹•–‡ƒ examinations.” Rdemonstrate the utility of a new approach that could make computed tomography (CT) scanning safer for patients. CT Bartolac S et al. Med Phys. 2011 Jul. Research supported by the Ontario technologies are routinely used for medical diagnostics and Graduate Scholarship Program and The Princess Margaret Hospital image guidance for interventional procedures. Advances have Foundation.

Using Smartphones in Hospitals ƥ ‹‡– ‘—‹ ƒ–‹‘„‡–™‡‡Š‡ƒŽ–Š ƒ”‡ Eworkers is critical for providing quality health care to patients. While the traditional means of communication rely on the use of a pager, the popularity of smartphones has led TGRI’s Drs. Dante Morra and Robert Wu to critically examine their use.

Residents, nurses, allied health professionals and attending physicians were given Blackberry smartphones. Researchers measured the frequency and type of communication between members of the medical units. Urgent issues were communicated through phone calls, while emails were used to ”‡Žƒ›‘Ǧ—”‰‡–‡••ƒ‰‡•ǤŠ‡•–—†›‹†‡–‹Ƥ‡† positive and negative consequences of smartphone use for clinical communication. There was an ƒ’’ƒ”‡–‹’”‘˜‡‡–‹‡ƥ ‹‡ ›‘˜‡”–Š‡—•‡‘ˆ pagers, with increased mobility and multi-tasking (L-R) Dr. Peter Rossos, Dr. Robert Wu, Sherman Quan, Vivian Lo and Dr. Dante Morra for residents and physicians. Negative outcomes included unprofessional smartphone use and †‹ơ‡”‡ ‡•”‡‰ƒ”†‹‰™Šƒ–™ƒ• ‘•‹†‡”‡†—”‰‡–Ǥ can begin developing systems to balance these and enhance health care through improved communication strategies.” ‘‡–‹‰‘–Š‡•‡Ƥ†‹‰•ǡ”Ǥ‘””ƒ•ƒ›•ǡDzƒ”–’Š‘‡ Wu R et al. J Med Internet Res. 2011 Aug. Research supported by the —•‡„›†‘ –‘”•‹–Š‡Š‘•’‹–ƒŽƒ’’‡ƒ”‡†–‘‹’”‘˜‡‡ƥ ‹‡ › Ontario Ministry of Health and Long-Term Care. of communication. While negative impacts were observed, we

31 INFORMATICS

Gene Signature Helps Predict –Š‡‡‡Ƥ–‘ˆŠ‡‘–Š‡”ƒ’›

‡ ‡–Ƥ†‹‰•ˆ”‘ Ȁ ’”‘˜‹†‡‹’‘”–ƒ–‡™ Rinformation that may help guide appropriate post-operative treatment for patients with early-stage (I and II) non-small-cell lung cancer (NSCLC). The research team, led by Drs. Ming-Sound Tsao and Frances Shepherd in collaboration with the NCIC Clinical Trials Group (CTG) in Kingston, conducted an in-depth analysis of gene expression from over 130 frozen tumour samples to determine if this pattern, or ‘signature’, of gene expression could help identify patients as high- or low-risk for cancer recurrence.

The researchers performed genomic analysis of lung tumour samples collected from Canadian patients participating in the NCIC CTG-led clinical trial, who did not receive chemotherapy ƒˆ–‡”•—”‰‡”›Ǥ•‡–‘ˆ͙͝‰‡‡•™ƒ•‹†‡–‹Ƥ‡†–Šƒ–’”‡†‹ –‡† which patients had aggressive cancers with a high risk of recurrence and death and which had less aggressive disease and a low risk of recurrence. The genetic signature was then applied to the group of patients who received post-operative Š‡‘–Š‡”ƒ’›ǤŠ‡”‡•—Ž–••Š‘™‡†–Šƒ–’ƒ–‹‡–•‹†‡–‹Ƥ‡†ƒ• high-risk by the signature had improved survival and derived •‹‰‹Ƥ ƒ–„‡‡Ƥ–ˆ”‘ Š‡‘–Š‡”ƒ’›Ǥ

DzŠ‹••–—†›•Š‘™•–Šƒ––Š‡͙͝‰‡‡•‹†‡–‹Ƥ‡†ƒ›Š‡Ž’ ƒ–‡‰‘”‹œ‡’ƒ–‹‡–•™‹–Š•–ƒ‰‡ ƒ†  ƒ ‡”™Š‘ƒ›„‡‡Ƥ– from post-operative chemotherapy and help other patients avoid potentially harmful treatment,” explains Dr. Tsao. “Importantly, –Š‡•‡Ƥ†‹‰•™‹ŽŽŠ‡Ž’—•‘˜‡‘‡•–‡’ Ž‘•‡”–‘’‡”•‘ƒŽ‹œ‡† medicine for patients.”

Zhu CQ et al. J Clin Oncol. 2010 Oct. Research supported by the Canadian Cancer Society, the US National Cancer Institute, the Canada Foundation for Innovation, the Canada Research Chairs Program, the Scott Taylor Chair in Lung Cancer Research, the Ontario Ministry of Health and Long-Term Care, GlaxoSmithKline and The Princess Margaret Hospital Foundation.

Drs. Frances Shepherd and Ming-Sound Tsao 32 Informatics-based Strategies to Identify Ovarian Cancer

individualized treatment regimens. Dr. Kislinger analyzed ’”‘–‡‹•‹ƒ• ‹–‹ ƪ—‹†•Ȅ ‡ŽŽ—Žƒ”ƪ—‹†•Ž‡ƒ‡†‹–‘–Š‡ spaces adjacent to a tissue of interest—as they were likely to be enriched with candidate biomarkers.

Using a technique called ‘shotgun proteomics’, where proteins are broken down into smaller components and then •‹—Ž–ƒ‡‘—•Ž›•‡’ƒ”ƒ–‡†ƒ†‹†‡–‹Ƥ‡†ǡƒ ‘’”‡Š‡•‹˜‡ description of the proteins within the ascites was formed. Ascitic samples from patients with malignant tumours were compared to benign tumour samples to identify unique biomarkers related to malignancy. Comparison of this data with existing data sets led to a prioritized list of 51 proteins (L-R) Drs. Patricia Shaw, Thomas Kislinger, Igor Jurisica and Blaise Clarke for further investigation. Dr. Kislinger’s research provides a pithelial ovarian cancer (EOC) is one of the most useful template for future proteomics-based discoveries of Ecommon types of cancer in women worldwide. Due to cancer biomarkers. the lack of a reliable early detection method, most cases of EOC are reported in the late stages of disease progression, Elschenbroich S et al. J Proteome Res. 2011 May. Research supported with tumours having spread beyond the ovaries. by the Canadian Institutes of Health Research, the Canada Foundation for Innovation, the Ministry of Research & Innovation Ontario Research Fund, the Ontario Ministry of Health and Long- Research from OCI Scientist Dr. Thomas Kislinger is focused Term Care, the Ontario Institute for Cancer Research, the Canada on discovering reliable biomarkers—indicators of disease Research Chairs Program and The Princess Margaret Hospital •–ƒ–‡•Ȅ–Šƒ–™‹ŽŽŽ‡ƒ†–‘‡ƒ”Ž›†‡–‡ –‹‘ƒ†‘”‡‡ƥ ‹‡–ǡ Foundation.

New Standards of Diagnosis for Renal Dysfunction iver cirrhosis, a condition from many †‡˜‡Ž‘’‡†‡™‰—‹†‡Ž‹‡•–‘‘ơ‡” Lcauses that results in scarring of the ‡ƒ”Ž‹‡”ƒ†‘”‡‡ơ‡ –‹˜‡‹–‡”˜‡–‹‘ liver, can lead to kidney malfunction. strategies. The most severe form is called hepatorenal syndrome (HRS), often The group proposed the use of the term associated with a fatal outcome. While “hepatorenal disorders” to describe current clinical practice limits drug all concurrent kidney dysfunction in treatment to patients with HRS, those patients with advanced liver disease. with milder kidney dysfunction could Explains Dr. Wong, “These broadened ƒŽ•‘„‡‡Ƥ–ˆ”‘–”‡ƒ–‡–Ǥ ‘™‡˜‡”ǡ †‡Ƥ‹–‹‘•™‹ŽŽŠ‡Ž’†‡•‹‰•–—†‹‡•–‘ –Š‡”‡ƒ”‡‘†‡Ƥ‡† ”‹–‡”‹ƒ–‘’”‘ ‡‡† assess the pathophysiology and devise with this broadened approach. treatment strategies for these patients, who can now be treated earlier, with To overcome this issue, a group of the potential for improved outcome and ‡š’‡”–•‹–Š‡Ƥ‡Ž†‘ˆ”‡ƒŽ†›•ˆ— –‹‘ survival.” ‹ ‹””Š‘•‹•ǡŽ‡†„›  ƥŽ‹ƒ–‡ Scientist Dr. Florence Wong, was formed Wong F et al. Gut. 2011 May. Research to assess and outline new standards for supported by Ikaria, Gambro Renal Care, the diagnosis of kidney malfunction in Otsuka Pharmaceutical, Nx-Stage Medical, IV patients with cirrhosis. The participating League Inc. and Baxter Inc. experts compiled information from Martha Orgill and Dr. Florence Wong previously published studies and

33 HEALTH SERVICES RESEARCH

Dr. Sherry Grace Optimizing Referral Strategies for Improved Cardiac Rehabilitation

ardiovascular rehabilitation, a combination of exercise and systematic and liaison strategies. The study found that the Clifestyle counselling for diet and medication adherence, ‘•–‡ơ‡ –‹˜‡•–”ƒ–‡‰›™ƒ•–Š‡ ‘„‹‡†”‡ˆ‡””ƒŽƒ’’”‘ƒ Šǡ reduces the risk of a repeat cardiac event and mortality in resulting in an 85.8% referral and 73.5% enrollment rate. ’ƒ–‹‡–••—ơ‡”‹‰ˆ”‘ ƒ”†‹‘˜ƒ• —Žƒ”†‹•‡ƒ•‡ǢŠ‘™‡˜‡”ǡ Š‡•‡—„‡”•™‡”‡•‹‰‹Ƥ ƒ–Ž›Š‹‰Š‡”–Šƒ–Š‡•–ƒ†ƒ”† patient referral and utilization remain low. A study from protocol rates of 32.2% referral and 29.0% enrollment. TGRI Scientist Dr. Sherry Grace has determined the optimal strategy for maximizing enrollment in cardiac rehabilitation Comments Dr. Grace, “Wider adoption of the strategies programs. examined in this study would increase enrollment in cardiac rehabilitation programs by up to 45%, providing major public ‘—”†‹ơ‡”‡–”‡ˆ‡””ƒŽ•–”ƒ–‡‰‹‡•™‡”‡‡šƒ‹‡†ǣƒ•–ƒ†ƒ”† health gains.” referral protocol; automatic referral, using standard orders or electronic patient records before hospital discharge; liaison Grace SL et al. Arch Intern Med. 2011 Feb. Research supported by the referral, facilitated through a personal discussion with a health Canadian Institutes of Health Research’s Institute of Gender and Health care professional; and a combined approach, using both and the Heart and Stroke Foundation of Canada.

34 Long-Term Health after Severe Lung Injury and Critical Illness

Work by TGRI’s Drs. Margaret Herridge, Angela Cheung ƒ† ‘ŽŽƒ„‘”ƒ–‘”•”‡˜‡ƒŽ‡†ˆ‘”–Š‡Ƥ”•––‹‡–Šƒ–ˆ‘” •—”˜‹˜‘”•‘ˆǡ†‹•ƒ„‹Ž‹–‹‡• ƒ ‘–‹—‡ˆ‘”—’–‘Ƥ˜‡ years after their critical illness. This is a follow-up of their initial one-year ARDS outcomes study. Patients who were free of other serious illnesses and employed before developing ARDS were often unable to return to work or maintain the same work schedule, had reduced physical health and showed signs of psychological trauma and emotional dysfunction, while incurring costs associated with health care that were comparable to people living with chronic disease. (L-R) Dr. Angela Cheung, Andrea Matté, Dr. George Tomlinson, Dr. Margaret Herridge and Catherine Tansey Š‡•‡Ƥ†‹‰•Š‹‰ŠŽ‹‰Š––Š‡‡‡†ˆ‘”ƒ‡™ƒ’’”‘ƒ Š‹ treating these patients—one that considers the long-term cute Respiratory Distress Syndrome (ARDS) is severe impact of acute ICU treatments and rehabilitation both A‹ƪƒƒ–‹‘‘ˆ–Š‡Ž—‰–Šƒ–‘ —”•‘•– ‘‘Ž›‹ during and after their ICU stay. response to serious infection and requires ventilator support and admission to the intensive care unit (ICU). Few follow-up Herridge MS et al. N Engl J Med. 2011 Apr. Research supported by studies exist that gauge the impact of ARDS on the long-term the Canadian Intensive Care Foundation, the Physicians’ Services health of survivors, their families, and their subsequent health Incorporated Foundation and the Ontario Thoracic Society. care use and associated costs.

The Importance of Mental Well-Being in Health Outcomes

otal joint replacement (TJR) can provide T•‹‰‹Ƥ ƒ–’ƒ‹”‡Ž‹‡ˆƒ†‹’”‘˜‡†ˆ— –‹‘‹ patients with osteoarthritis, a very common joint disorder. A recent study by TWRI Senior Scientist Dr. Elizabeth Badley, designed and completed by UHN Arthritis Program epidemiologist Dr. Anthony Perruccio and Senior Scientist Dr. Aileen Davis, has examined the role of mental well-being, physical and social health and self-rated health (SRH) as indicators of future health in patients undergoing TJR.

Patients were assessed before surgery and three and six months after surgery using questionnaires measuring SRH and factors of physical, social and mental health. Those who recorded a low SRH score before their operation were found to have less improvement in outcomes post-surgery. (L-R) Drs. Aileen Davis, Anthony Perruccio and Elizabeth Badley Furthermore, the study indicated that assessment of mental well-being served as an important predictor of SRH. Ƥ†‹‰•ˆ”‘–Š‹••–—†›•—‰‰‡•––Šƒ–™‡‡‡†–‘’ƒ›‘”‡ attention to overall health and mental well-being,” comments Š‡•‡Ƥ†‹‰•Š‹‰ŠŽ‹‰Š––Š‡‡“—ƒŽ‹’‘”–ƒ ‡‘ˆ ǡ‡–ƒŽ Dr. Perruccio. well-being and physical health as essential factors contributing to the health status of patients recovering from TJR. “Focusing Perruccio AV et al. Arthritis Care Res. 2011 Jul. Research supported by on only one health aspect, such as pain, may lead to missed the Canadian Institutes of Health Research. opportunities for improving outcomes after surgery. The

35 38 INSTITUTES

UHN Research is organized on a multi-institute model. Each Š‘•’‹–ƒŽŠƒ•ƒƒƥŽ‹ƒ–‡†”‡•‡ƒ” Š‹•–‹–—–‡Ǥ •–‹–—–‡•Šƒ˜‡ separate governance structures but all are under the direction of UHN’s Vice President, Research. The following pages describe our Institutes.

Ontario Cancer Institute

Toronto General Research Institute

Toronto Western Research Institute

37 Ontario Cancer Institute

Senior Scientists Howell, Doris Chan, Kelvin Gupta, Vikas Pendergrast, Jacob Arrowsmith, Cheryl Kislinger, Thomas Chang, Hong Hales, Sarah Perez-Ordonez, Asa, Sylvia Koch, Anne Chen, Christine Hodgson, David Bayardo Barber, Dwayne ‹—ǡ ‡‘ơ”‡› Cheung, Carol Hofer, Stefan Pierre, Andrew Boyd, Norman Moghal, Nadeem Cho, Charles Hogg, David Rasty, Golnar Bristow, Robert O’Brien, Catherine Cho, John Hope, Andrew Reece, Donna Chakrabartty, Avijit Raught, Brian Chung, Caroline Irish, Jonathan Ridley, Julia Devins, Gerald Stambolic, Vuk Chung, Peter Jewett, Michael Ringash, G Jolie Dick, John Tiedemann, Rodger Cil, Tulin Jones, Jennifer Rosen, Barry Ezzat, Shereen Tillier, Elisabeth Clarke, Blaise Joshua, Anthony Rotstein, Lorne Gagliese, Lucia Trudel, Suzanne Cleary, Sean Kassam, Zahra Rouzbahman, Marjan Gallie, Brenda Zimmermann, Camilla Croul, Sidney Kaya, Ebru Ruschin, Mark Hakem, Razqallah ƥŽ‹ƒ–‡ ‹‡–‹•–• Crump, R Michael Keating, Armand Sahgal, Arjun Cserti, Christine Kennedy, Erin Hedley, David Bradley, Grace Santos, Gilda Cummings, Bernard Keshavjee, Shaf Hill, Richard Chen, Eric Schuh, Andre Czarnota, Gregory Kiehl, Tim-Rasmus Hunt, John Esplen, Mary Jane Seccareccia, Dori D’Agostino, Norma Kim, Dennis Ikura, Mitsuhiko Gauthier, Mona Serra, Stefano Iscove, Norman Darling, Gail Kim, John Shaw, Patricia Martin, Lisa Dawson, Laura Knox, Jennifer ƒơ”ƒ›ǡƒ˜‹† Moore, Malcolm Shepherd, Frances Jurisica, Igor de Perrot, Marc Krzyzanowska, Simpson, E Rand Moran, Michael Dinniwell, Robert Monika Kamel-Reid, Suzanne Reedijk, Michael Siu, Lillian Keller, Gordon Dodge, Jason Kukreti, Vishal Sridhar, Srikala Ritvo, Paul Done, Susan Kuruvilla, John Khokha, Rama Strevel, Elizabeth Sherar, Michael Easson, Alexandra Laframboise, Lilge, Lothar Sun, Alexander Wang, Jean Elantholi Stephane Liu, Fei-Fei Sutherland, D Robert Xu, Wei Parameswaran, Laperriere, Normand Mak, Tak Swallow, Carol Assistant Scientists Saibishkumar Leighl, Natasha Manoukian, Armen Sweet, Joan Araki, Toshiyuki Elliott, Mary Leong, Wey-Liang ‡†‹ǡ ‡ơ”‡› Taremi, Mojgan Dacosta, Ralph Elser, Christine Levin, Wildred Messner, Hans Taylor, Bryce Hao, Zhenyue El-Zimaity, Hala Li, Madeline Minden, Mark Torlakovic, Emina Escallon, Jaime Lindsay, Patricia Minkin, Salomon Clinical Resource Trachtenberg, John Evans, Andrew ‹’–‘ǡ ‡ơ”‡› Muthuswamy, Senthil Unit (CRU) Feld, Ronald Lo, Christopher Tsang, Richard Neel, Benjamin Members Fenkell, Louis Mackay, Helen Tsao, May Ohashi, Pamela Baker, Michael Ferguson, Peter Mak, Ernie van der Kwast, Okada, Hitoshi Banerjee, Subrata Ferguson, Sarah Manchul, Lee Theodorus Pai, Emil Barth, David Finelli, Antonio Mason, Warren Waddell, Thomas Paige, Christopher Bayley, Andrew Fleshner, Neil Matthew, Andrew Waldron, John Penn, Linda Bedard, Philippe Freeman, Jeremy McCart, J Andrea Ward, Richard Privé, Gilbert Bell, Robert Fyles, Anthony McCready, David Warde, Padraig Rodin, Gary Berman, Hal Gaind, Sonu McGilvray, Ian Warr, David Rottapel, Robert Bernardini, Marcus Gallinger, Steven McLean, Linda Wei, Alice Schimmer, Aaron Bernstein, Lori Geddie, William McLean, Michael Weinreb, Ilan Tannock, Ian Bernstein, Mark Gentili, Fred McLeod, Robin Wells, Woodrow Till, James Bezjak, Andrea Ghazarian, Danny Melnyk, Tatiana Witterick, Ian Tsao, Ming-Sound Blackstein, Martin Gilbert, Ralph Ménard, Cynthia Wong, Rebecca Vitkin, I Alex Boerner, Scott Gladdy, Rebecca Millar, Barbara-Ann Wood, Robert Wilson, Brian Brade, Anthony Goldstein, David Miller, Kim Wunder, Jay Wouters, Bradly Brandwein, Joseph Goodwin, Pamela Miller, Naomi Yasufuku, Kazuhiro Zheng, Gang Brien, William Gospodarowicz, Mary Milosevic, Michael Yee, Karen Scientists Brierley, James Grant, David Moulton, Carol-Anne Yeo, Erik Ailles, Laurie Brown, Dale Greig, Paul Murphy, K Joan Youngson, Bruce Brock, Kristy Bryson, John Gryfe, Robert Olivieri, Nancy Zadeh, Gelareh Cheung, Peter Burkes, Ronald Guha, Abhijit O’Sullivan, Brian Zhong, Toni Edelstein, Kim Catton, Charles Gullane, Patrick Oza, Amit Zlotta, Alexandre Hirano, Naoto Catton, Pamela Gupta, Abha Payne, David 38 Research Space 373,000 square feet Total External Funding $101,502,000 872 Publications 48 Senior Scientists 17 Scientists 12 ƥŽ‹ƒ–‡ ‹‡–‹•–• 3 Assistant Scientists 182 CRU Members 262 Total Researchers 190 Fellows 191 Graduate Students 381 Total Trainees 684 ‘–ƒŽ–ƒơ

Research Council on Oncology (RCO) Director, OCI; Chair, RCO; Robert Rottapel Clinical Representative, Vice President, PMH Director, Executive Committee Brian Wilson Medical Oncology and Sarah Downey Bradly Wouters Benjamin Neel Hematology Executive Director, Research Executive Committee Members Clinical Representative, Malcolm Moore Operations Mitsuhiko Ikura Pathology Clinical Representative, Lisa Alcia Senthil Muthuswamy Sylvia Asa Surgical Oncology Vice President, Research Pamela Ohashi Clinical Representative, Jonathan Irish Christopher Paige Linda Penn Gary Rodin Radiation Oncology CCRU Representative Mary Gospodarowicz Amit Oza Toronto General Research Institute

Behavioural Levy, Gary Scientists Chan, Charles Genomic Sciences & Liles, W Conrad Alibhai, Shabbir Chan, Christopher Medicine Liu, Mingyao Chauhan, Vijay Health Urbach, David Senior Scientists Rubin, Barry ƥŽ‹ƒ–‡ ‹‡–‹•–• Cooper, Richard Senior Scientists Waddell, Thomas Djaiani, George Kain, Kevin Gagliardi, Anna Flint, Alastair Wheeler, Michael Fedorko, Ludwik MacDonald, Kelly Kennedy, Erin Kaplan, Allan Zacksenhaus, Eldad Harris, Louise Pei, York Lok, Charmaine Olmsted, Marion Zhang, Li Herridge, M Margaret Siminovitch, Rodin, Gary Tomlinson, George Katherine Scientists Wei, Alice Ing, Douglas Stewart, Donna Jassal, S Vanita Scientist Dunn, Shannon Clinical Studies Scientists Karski, Jacek Kaul, Rupert Fish, Jason Resource Centre Carter, Jacqueline Kotra, Lakshmi McCluskey, Stuart ƥŽ‹ƒ–‡ ‹‡–‹•–• Esplen, Mary Jane (CSRC) Members McRae, Karen Lam, Tony Boright, Andrew Grace, Sherry Jewett, Michael Parker, John Lee, Douglas Downey, Gregory ƥŽ‹ƒ–‡ ‹‡–‹•–• Volchuk, Allen Kapral, Moira Salit, Irving Singer, Lianne Osborne, Lucy Baker, Brian ƥŽ‹ƒ–‡ ‹‡–‹•–• Seidelin, Peter Sherman, Morris Clinical Studies Carnahan, Heather Belsham, Denise Clinical Siu, Samuel Resource Centre Colton, Patricia Branch, Donald Investigation Slinger, Peter (CSRC) Members Davis, Caroline Chang, Hong Gucciardi, Enza & Human Bargman, Joanne Chow, Chung-Wai Physiology Experimental Hall, Peter Clark, David Beattie, W Scott Heslegrave, Ron Cole, Edward Senior Scientists Therapeutics Brister, Stephanie Hodges, Brian Feld, Jordan Allard, Johane Senior Scientists Colman, Jack Irvine, M Jane Ghanekar, Anand Bradley, T Douglas Keating, Armand David, Tirone Jones, Jennifer Gramolini, Anthony Cattran, Daniel Kelvin, David Dzavik, Vladimir Katz, Joel Husain, Shahid Easty, Anthony Keshavjee, Shaf Fenton, Stanley Kovacs, Adrienne Jin, Tianru Fisher, Joseph Li, Ren-Ke Gardam, Michael McVey, Gail Lee, Ping Floras, John Lindsay, Thomas Gold, Wayne Nolan, Robert Phillips, James Kucharczyk, Walter Liu, Peter Goldszmidt, Eric Styra, Rima Rocheleau, Jonathan Lewis, Gary Rao, Vivek Granton, John Woodside, D Blake Rotstein, Coleman Miller, Judith von Harsdorf, Rüdiger Grigoriadis, Sophie Selzner, Markus Olivieri, Nancy Weisel, Richard Kachura, John Cellular & Walmsley, Sharon Kennedy, Sidney Assistant Scientist Scientists Molecular Scientist Keystone, Edward Biology Serghides, Lena de Perrot, Marc Karkouti, Keyvan Lilly, Leslie Senior Scientists McCart, J Andrea O’Malley, Martin Clinical ƥŽ‹ƒ–‡ ‹‡–‹•–• McGilvray, Ian Backx, Peter Rajan, Dheeraj Decision-Making McGowan, Cheri Nanthakumar, Berger, Stuart Rakowski, Harry & Health Care Perkins, Bruce Kumaraswamy Cardella, Carl Ralph-Edwards, Raboud, Janet Yau, Terrence Cattral, Mark Senior Scientists Anthony Reilly, Raymond Cybulsky, Myron Bombardier, Claire ƥŽ‹ƒ–‡ ‹‡–‹•–• Richardson, Robert Sawka, Anna Dick, John Cheung, Angela Fremes, Stephen Roberts, Heidi Wong, Florence Fantus, I George Daar, Abdallah Hwang, David Ross, John Fish, Eleanor Eysenbach, Gunther Clinical Studies ‡†‹ǡ ‡ơ”‡› Straus, Sharon Gorczynski, Reginald Jadad, Alejandro Resource Centre Radisic, Milica Sweet, Joan Gotlieb, Avrum Krahn, Murray (CSRC) Members Ross, Heather Wolman, Stephen Grant, David Naglie, I Gary Bril, Vera Sefton, Michael Yeo, Erik Husain, Mansoor Singer, Peter Cameron, Douglas Yasufuku, Kazuhiro

40 Research Space 267,000 square feet Total External Funding $59,762,000 765 Publications 57 Senior Scientists 18 Scientists 53 ƥŽ‹ƒ–‡ ‹‡–‹•–• 1 Assistant Scientist 51 CSRC Members 180 Total Researchers 156 Fellows 111 Graduate Students 267 Total Trainees 410 ‘–ƒŽ–ƒơ

TGRI Research Council

Director, TGRI; Chair, Division Head, Cell and Department Medical Clinical Representative, Li Zhang TGRI Research Council Molecular Biology Director, Peter Munk Transplant Unit, Vice President, TGH Mansoor Husain Eleanor Fish Cardiac Centre Platform Leader Marnie Escaf Division Head, Division Head (interim), Barry Rubin Gary Levy Ian McGilvray Executive Director, Behavioural Sciences & Clinical Investigation Clinical Representative, Research Operations Health and Human Physiology; Medical and Community Standing Guests Lisa Alcia Gary Rodin and Experimental Care Reginald Gorczynski Therapeutics W Conrad Liles Tony Lam Vice President, Research Division Head, Clinical Christopher Paige Richard Weisel Ren-Ke Li Decision-Making & Clinical Representative, Mingyao Liu Health Care Division Head, Genomic Surgical and Critical Vivek Rao Claire Bombardier Medicine Care Jonathan Rocheleau Katherine Siminovitch Shaf Keshavjee Thomas Waddell Toronto Western Research Institute

Brain, Imaging & Eubanks, James Ferguson, Niall Graham, Brent Behaviour - Systems Fehlings, Michael Tarlo, Susan Hawa, Raed Inman, Robert Iwanochko, R Mark Neuroscience Jongstra, Jan Vision Science Lam, Robert Senior Scientists Schlichter, Lyanne Senior Scientists Lam, Wai-Ching Stanley, Elise Manninen, Pirjo Brotchie, Jonathan Flanagan, John Tator, Charles Massicotte, Eric Chen, Robert Flannery, John Tsui, Florence McGuire, Glenn Davis, Karen Sharpe, James McIntyre, Roger Hutchison, William Wither, Joan Steinbach, Martin Melvin, Kenneth Lozano, Andres Scientist Trope, Graham Miyasaki, Janis McAndrews, Mary Pat Monnier, Philippe Wong, Agnes Mikulis, David Moro, Elena Scientists Sandor, Paul Oandasan, Ivy Health Care & Hudson, Christopher Strafella, Antonio Ogilvie, Richard Outcomes Research Sivak, Jeremy Ogilvie-Harris, Darrell ƥŽ‹ƒ–‡ ‹‡–‹•–• Senior Scientists ƥŽ‹ƒ–‡ ‹‡–‹•–• Panisko, Daniel De Nil, Luc Badley, Elizabeth Eizenman, Moshe Parikh, Sagar Dostrovsky, Jonathan Cassidy, J David Gallie, Brenda Peng, Philip Kucharczyk, Walter Davis, Aileen Irving, Elizabeth Radomski, Sidney Saint-Cyr, Jean Fortin, Paul Wilkinson, Frances Rampersaud, Yoga Raja Gignac, Monique Rootman, David Fundamental Gladman, Dafna Clinical Studies Rosen, Cheryl Neurobiology Mahomed, Nizar Resource Centre Saltzman-Benaiah, Jennifer Senior Scientists Urowitz, Murray (CSRC) Seyone, Chanth Scientist Silver, Frank Broussard, Dianne Members Simons, Martin Carlen, Peter Côté, Pierre Anastakis, Dimitrios Singer, Shaun Skinner, Frances ƥŽ‹ƒ–‡ ‹‡–‹•–• Bookman, Arthur Slomovic, Allan Sugita, Shuzo Cott, Cheryl Buys, Yvonne St George-Hyslop, Peter Tymianski, Michael Lineker, Sydney Chan, Vincent Stanbrook, Matthew ƥŽ‹ƒ–‡ ‹‡–‹•–• Martino, Rosemary Chapman, Kenneth Stubbs, Barbara Gaisano, Herbert Chung, Frances Syed, Khalid Hassouna, Magdy Patient Based Clinical Davey, J Roderick Terbrugge, Karel ƒŽ‹ƒ–‡ǡƒ—Ƥ Research del Campo, Jose Martin Tu, Karen Zhang, Liang Senior Scientists Devenyi, Robert Tumber, Paul Epstein, Trina von Schroeder, Herbert Diamant, Nicholas Escallon, Jaime Wherrett, John Genetics & Heathcote, Jenny Etlin, David Willinsky, Robert Development Lang, Anthony Evans, Michael Wong, David Shapiro, Colin Senior Scientists Farb, Richard Wong, Jean Barr, Cathy Scientists Fung, Ken Yu, Eric Bremner, Rod Bernstein, Mark Gentili, Fred

TWRI Research Council

Director, TWRI; Chair, TWRI Division Head, Fundamental Division Head, Vision Science Clinical Representative, Research Council Neurobiology Martin Steinbach Musculoskeletal Health & Peter St George-Hyslop Peter Carlen Clinical Representative, Arthritis Program Division Head, Health Care & Division Head, Brain Imaging & Krembil Neuroscience Robert Inman Outcomes Research Behaviour - Systems Program Senior Director, Finance Elizabeth Badley Neuroscience Michael Fehlings Peggy McGill Division Head, Genetics & Karen Davis Clinical Representative, Vice President, TWH Development Division Head, Patient Based Musculoskeletal Program Kathy Sabo Rod Bremner Clinical Research Nizar Mahomed Vice President, Research 42 Jenny Heathcote Christopher Paige Research Space 105,000 square feet Total External Funding $43,612,000 515 Publications 43 Senior Scientists 7 Scientists 15 ƥŽ‹ƒ–‡ ‹‡–‹•–• 57 CSRC Members 122 Total Researchers 87 Fellows 70 Graduate Students 157 Total Trainees 206 ‘–ƒŽ–ƒơ 44 Financial Information

Total Project Funding Awarded (by type, in thousands)

Total $204,876

UHN Foundations $45,061 $23,871 Clinical Studies

Career/Traineeship $7,813 Awards $6,750 Corporate Contacts

Other $5,846 $17,244 Infrastructure/Maintenance Awards $98,291 Operating Grants

Research Core/TMDT Operating Funding (in thousands)

Total $48,369

Rental Income $5,531 $6,511 Other

Ministry of Health and $2,816 $4,800 Canadian Institutes of Health Long-Term Care Research, Indirect Funds

Investment Income $2,064 $670 Provincial Indirect Cost Grant

Arthritis & Autoimmunity $1,000 $5,600 Canada Foundation for Innovation - Research Centre Foundation Infrastructure Operating Funds

Princess Margaret Hospital $16,332 $3,043 Toronto General & Western Hospital Foundation Foundation

ŽŽƤ‰—”‡•”‡’”‡•‡–Ƥ• ƒŽ›‡ƒ”͚͙͘͘Ȁ͙͙ƒ†‹ Ž—†‡–ƒ”‹‘ƒ ‡” •–‹–—–‡ȋ”‹ ‡••ƒ”‰ƒ”‡– ‘•’‹–ƒŽȌǡ‘”‘–‘ ‡‡”ƒŽ‡•‡ƒ” Š •–‹–—–‡ȋ‘”‘–‘ ‡‡”ƒŽ Hospital), Toronto Western Research Institute (Toronto Western Hospital) and Toronto Medical Discovery Tower (TMDT). Figures may not sum due to rounding. Š‡•‡Ƥ‰—”‡•Šƒ˜‡„‡‡’”‘˜‹†‡†„› ‡•‡ƒ” Š ‹ƒ ‹ƒŽ‡”˜‹ ‡•ǤŠ‡•‡Ƥ‰—”‡•Šƒ˜‡‘–„‡‡ƒ—†‹–‡†Ǥ ‘™‡˜‡”ǡ–Š‡›Šƒ˜‡„‡‡‹ Ž—†‡†‹–Š‡‘˜‡”ƒŽŽ  statements and have been subjected to audit procedures deemed appropriate by auditors in order to determine their overall reasonableness. 45 UHN Research Committees

Animal Care Committee (OCI) Cancer Clinical Research Unit Data Safety Monitoring Committee Hill, Richard (Co-Chair) Management Committee Knox, Jennifer (Co-Chair) Iscove, Norman (Co-Chair) Degendorfer, Pamela (Chair) Sun, Alex (Co-Chair) Bailey, Monica Cheiken, Robin Cheiken, Robin Brock, Kristy Cole, Heather Hersey, Karen Hedley, David Croft, Sarah Wang, Lisa Martin, Lisa Flynn-Post, Marcia ‘Ž‡ǡ ‡ƒ–Š‡”ȋ‡šǦ‘ƥ ‹‘Ȍ Moloo, Badru Hersey, Karen Multidisciplinary Research Ethics Moriyama, Beryl Molnar, Margaret Tillier, Elisabeth Nagai, Jane Board “A” Zheng, Gang Piza Rodriguez, Jesus Giovanni McRae, Karen (Co-Chair) Braganza, Sharon Animal Care Committee (TGH, TWH) Purushuttam, Linda Sauter, Agnes Campbell, Michael ‡†‹ǡ ‡ơ”‡›ȋŠƒ‹”Ȍ Sellmann, Susanna Cathcart, Derek Cybulsky, Myron (Co-Chair) Stewart, Jan Cherney, David Cook, Kathleen Cusimano, Robert Dray, Richard (Community Representative) Cancer Registry and Data Access Downar, James Dunn, Shannon Committee Friedman, Steven Galligan, Carol Fung, Scott Brierley, James (Chair) Gorczynski, Reginald Giacobbe, Peter McCart, J Andrea Dale, Darlene (Co-Chair) Lok, Charmaine Moloo, Badru Agelastos, Niki Sampson, Heather Monnier, Philippe Easson, Alexandra Seto, Ronald Rocheleau, Jonathan Eggert, Calven Sloss, Elizabeth Schlichter, Lyanne Goldstein, David Tung, Jennifer Sugita, Shuzo Gupta, Vikas ƒŽ‹ƒ–‡ǡƒ—Ƥ Hodgson, David Virtanen, Carl Appointments Committee (OCI) Krzyzanowska, Monika Wijeysundera, Duminda Liu, Fei-Fei (Chair) Panzarella, Tony Wolman, Stephen Iscove, Norman Perez-Ordonez, Bayardo Zamel, Noe ƒơ”ƒ›ǡƒ˜‹† Shaw, Patricia Khokha, Rama Multidisciplinary Research Ethics Mak, Tak Clinical Studies Quality Committee Board “B” Minden, Mark Paige, Christopher (Chair) McRae, Karen (Co-Chair) Privé, Gilbert Chan, Charles (Chair) Anstey, Kyle Rodin, Gary Alcia, Lisa Bargman, Carol Neel, Benjamin (‡šǦ‘ƥ ‹‘) Clarke, Rosemarie Baron, Ruth Anne Fleshner, Neil Barth, David Cancer Clinical Research Unit Floras, John Fedorko, Ludwik Executive Fox, Susan Gandhi, Rajiv Oza, Amit (Chair) Granton, John Hassouna, Magdy Brandwein, Joseph Habal, Flavio Hutcheon, Michael Brierley, James Kucharczyk, Walter Hutchison, William Degendorfer, Pamela Martin, Bella Lok, Charmaine Fitzgerald, Barbara Matte, Andrea Marras, Connie Knox, Jennifer Musing, Emily McIntyre, Roger O’Malley, Martin Oza, Amit Naraghi, Ali Reedijk, Michael Piza Rodriguez, Jesus Giovanni Parker, John Sultan, Roxanna Roposa, Katie Rapaport, Lesley van der Kwast, Theodorus Siu, Lillian Rivkin, Elena Wong, Rebecca Sherman, Morris Zimmermann, Camilla Wooster, Douglas

46 Oncology Research Ethics Board “C” ‹—ǡ ‡‘ơ”‡› Liu, Mingyao Holland, Jack (Co-Chair) Shaw, Patricia Paige, Christopher Amir, Eitan Tsao, Ming-Sound Rodin, Gary Brade, Anthony Weisel, Richard Buckley, Carol Ann Ad-Hoc Members: Zhang, Li Chu, Kwun Ye Asa, Sylvia Darling, Gail Bailey, Denis TWRI Appointments Committee DeLuca, Stephanie Boerner, Scott Lozano, Andres (Chair) ‹‘ǡ ‡ơ”‡› Bristow, Robert Badley, Elizabeth Feld, Ronald Butany, Jagdish Berger, Stuart Findlay, Andrea Chetty, Runjan Bremner, Rod Le, Lisa Croul, Sidney Carlen, Peter Mackay, Helen Crump, Michael Davis, Karen Mason, Warren Ezzat, Shereen Heathcote, Jenny McLean, Michael Fyles, Anthony St George-Hyslop, Peter Miller, Naomi Gallie, Brenda Steinbach, Martin Razak, Albiruni Ghazarian, Danny Robinson, Gordon Gilbert, Ralph TWRI Space Committee Short, Donald Guha, Abhijit Eubanks, James (Chair) Wei, Alice Guindi, Maha Broussard, Dianne Yee, Karen Heathcote, Jenny Chen, Robert Zaman, Faraz Hedley, David Gignac, Monique Johnston, Michael McDermott, Ian Radionuclide Safety Committee Minden, Mark Steinbach, Martin Murphy, Janet Burke, Ron Vidic, Frank O’Sullivan, Brian Capone, Gina Wither, Joan Chong, Perry Perez-Ordonez, Bayardo Fountas, Mary Sweet, Joan Gabrys, Judith Tkachuk, Douglas  ”ƒ‹‡‡ơƒ‹”•‘‹––‡‡ Green, David Youngson, Bruce Strafella, Antonio (Chair) Iscove, Norman Yucel, Yeni Adleman, Alanna McDermott, Ian Alavi, Mahan Wilson, David Research Risk and Audit Committee Bhardwaj, Renu Bercasio, Vanessa (Administrative Support) Christopher, Leigh Alcia, Lisa (Chair) Johnson, Karen-Ann (Guest) Cockburn, Diane Roposa, Katie (Co-Chair) Tourneur, Frank (Guest) DeSouza, Danielle Bhardwaj, Renu Fan, Susan Campbell, Chip Figley, Sarah Research Biosafety Committee Donohue, Evan Hutchison, William Brunton, James (Chair) Fischer, Gabriella Jong, Monica Hakem, Razqallah Goldthorpe, Tom Khuu, Lee-Anne Lemieux, Camille Goncalves, Tony Kucyi, Aaron ‡†‹ǡ ‡ơ”‡› MacPherson, Paul Moayedi, Massieh Shannon, John McDermott, Ian Pau, Evelyn Wither, Joan McGill, Peggy Rosen, Allie Bilan, Richard (‡šǦ‘ƥ ‹‘) Moloo, Badru Rozanski, Gabriela McDermott, Ian (‡šǦ‘ƥ ‹‘) Speers, Vanessa —ơǡ”›•–ƒŽ Moloo, Badru (‡šǦ‘ƥ ‹‘) Vespa, John Skinner, Frances Srejic, Luka Research Ethics Board Human TGRI Appointments Committee Tran, Chris Tissue Committee Waddell, Thomas (Chair) Vetiska, Sandra Cheung, Carol Fish, Eleanor Vasudeva, Manoj Henry, Michele Husain, Mansoor Wan, Julie Khokha, Rama Liles, W Conrad

47 External Sponsors

Abbott Laboratories Bioniche Therapeutics Chroma Therapeutics Abiomed Bio-Rad Laboratories CIHR Canadian HIV Trials Network Actelion Pharmaceuticals Canada BioTheryX Colon Cancer Canada ActiViews Biotronik Canada Cougar Biotechnology Advanced Neuromodulation Systems Boehringer Ingelheim Covidien Aegera Therapeutics Bracco Diagnostic CReATe Cord Blood Bank Alberta Innovates - Health Solutions Brain Tumour Foundation of Canada Crohn’s and Colitis Foundation of Canada Allergan Sales Breast Cancer Research Foundation CSL Behring Alnylam Pharmaceuticals Bristol-Myers Squibb Canada Cubist Pharmaceuticals Alzheimer Society of Canada Canada Foundation for Innovation Cylex Ambit Biosciences Canada Research Chairs Program Dystonia Medical Research Foundation American Association of Neurological Canadian Anesthesiologists’ Society Edwards Lifesciences Surgeons Canadian Arthritis Network Eisai American Society of Colon and Rectal Canadian Association of Nurses in Elekta Surgeons Oncology Eli Lilly Canada American Society of Hematology Canadian Association of Radiation EntreMed American Society of Transplant Surgeons Oncology Enzon Pharmaceuticals Amgen Canada Canadian Blood Services Facet Biotech Amicus Therapeutics Canadian Breast Cancer Foundation FIENS Anthera Pharmaceuticals Canadian Breast Cancer Research Alliance Fio AOSpine International Canadian Cancer Society Research Institute Foundation Fighting Blindness APT Pharmaceuticals Canadian Cystic Fibrosis Foundation Fred Hutchinson Cancer Research Center Argonne National Laboratory Canadian Diabetes Association GE Healthcare Arius Research Canadian Institutes of Health Research Genentech ArQule Canadian Liver Foundation Genome Canada Arthritis and Autoimmunity Research Canadian Neuromodulation Society Genta Centre Foundation (Arthritis Canadian Partnership Against Cancer Genzyme Canada Research Foundation) Canadian Patient Safety Institute Gilead Sciences Arthritis Society Canadian Pulmonary Fibrosis Foundation Glaucoma Research Society of Canada ASPEN Rhoads Research Foundation Canadian Stroke Network GlaxoSmithKline Association for International Cancer Canadian Urologic Oncology Group Government of Ontario Research CanBas Hana Biosciences Association of Faculties of Medicine of Cancer Care Ontario Heart & Stroke Foundation Canada Cancer Research Society Holistic Health Research Foundation of Astellas Pharma Canada Cardiokine Canada AstraZeneca Canada CareFusion Hospital for Sick Children Atuka Celgene Howard Hughes Medical Institute Aviva Canada Celsion Humber College Baxter Healthcare Centre for Addiction and Mental Health Hypertension Canada Bayer Centers for Disease Control and Prevention Idenix Pharmaceuticals Beckman Research Institute of City of Hope Cephalon Incyte Benvenue Medical Cervical Spine Research Society Informa Bill & Melinda Gates Foundation ChemGenex Pharmaceuticals Innovive Pharmaceuticals Biogen Idec Christopher and Dana Reeve Foundation Insurance Bureau of Canada

48 Intercept Pharmaceuticals Council Roche InterMune NCIC Clinical Trials Group at Queen’s Royal College of Physicians and Surgeons International Association for the Study of University of Canada Lung Cancer Networks of Centres of Excellence of Royal College of Surgeons of Ireland International Rett Syndrome Foundation Canada Rutgers International Science and Technology Neuroradiology Education and Research Salix Pharmaceuticals Partnerships Canada Foundation ƒ‘ƤǦƒ˜‡–‹• Janssen NoNO Schering-Plough Canada Johnson & Johnson Pharmaceutical Northern Therapeutics Scottish Rite Charitable Foundation Research and Development NovaLung Seattle Genetics Juvenile Diabetes Research Foundation Novartis Sentinel Oncology Canada Novo Nordisk Canada Sentinelle Medical KAI Pharmaceuticals NPS Pharmaceuticals Servier Canada Kidney Foundation of Canada Olympus Social Sciences & Humanities Research Korea Institute for Advancement of Ontario Association of Medical Council Technology Laboratories Society of American Gastrointestinal and Lady Tata Memorial Trust Ontario Centres of Excellence Endoscopic Surgeons Laval University Ontario Clinical Oncology Group Solutions By Sequence Leukemia & Lymphoma Society Ontario Consortium for Image Guided St. Jude Medical Lumen Therapeutics Therapy and Surgery Stryker Biotech Lundbeck Canada Ontario Genomics Institute Sunnybrook Health Sciences Centre Lupus Foundation of America Ontario HIV Treatment Network Susan G. Komen Breast Cancer Foundation Lupus Ontario Ontario Innovation Trust Taylor & Frances Group MaRS Innovation Ontario Institute for Cancer Research Terry Fox Research Institute Mayo Clinic Ontario Lung Association Terumo Cardiovascular Systems McEwen Centre for Regenerative Medicine Ontario Mental Health Foundation Teva Neuroscience McGill University Health Centre Ontario Neurotrauma Foundation Thallion Pharmaceuticals McMaster University Ontario Psychiatric Outreach Program Thoratec Medivation Onyx Pharmaceuticals Threshold Pharmaceuticals Medtronic Osiris Therapeutics Tibotec Pharmaceuticals Merck Otsuka Pharmaceutical Toronto Dementia Research Alliance Mesothelioma Applied Research Ottawa Hospital Research Institute Toronto General & Western Hospital Foundation Paracor Medical Foundation Michael J. Fox Foundation for Parkinson’s Parexel Toshiba Medical Systems Research Parkinson Society Canada Trillium Therapeutics MicroVention Partners HealthCare United States Army Medical Research Miikana Therapeutics Ƥœ‡”ƒƒ†ƒ Acquisition Activity Millennium Pharmaceuticals Philips Electronics North America United States Department of Defense Ministry of Finance - Financial Services Physicians’ Services Incorporated UCB Pharma Commission of Ontario Foundation University of California, Los Angeles Ministry of Health and Long-Term Care Pierre Fabre Médicament University of California, San Diego Ministry of Research and Innovation Princess Margaret Hospital Foundation University of Texas at Austin Mitsubishi Tanabe Pharma Procter & Gamble Pharmaceuticals University of Toronto Molecular Insight Pharmaceuticals Prostate Cancer Canada Vertex Pharmaceuticals Mount Sinai Hospital Proteolix Vision Science Research Program Multiple Sclerosis Society of Canada Proteomic Methods Vitrolife National Institutes of Health Public Health Agency of Canada W.L. Gore & Associates National Parkinson Foundation Purdue Pharma Canada Workplace Safety and Insurance Board National Sanitarium Association Questcor Pharmaceuticals Wyeth Canada National Surgical Adjuvant Breast and Quintiles YM BioSciences Bowel Project RaySearch Laboratories Younger Foundation Natural Sciences and Engineering Research Rick Hansen Foundation We are a caring, creative and accountable University Health Network is a teaching academic hospital, transforming health care for Š‘•’‹–ƒŽƒƥŽ‹ƒ–‡†™‹–Š–Š‡‹˜‡”•‹–›‘ˆ our patients, our community and the world. Toronto.

University Health Network ƥ ‡‘ˆ–Š‡‹ ‡”‡•‹†‡–ǡ‡•‡ƒ” Š Research Report 2011 University Health Network 610 University Avenue www.uhnresearch.ca 7th Floor, Room 7-504 Toronto, Ontario, Canada M5G 2M9

52